

1 **Characterisation of *l(3)tb* as a novel tumour suppressor allele of *DCP2* in *Drosophila melanogaster***

2 Rakesh Mishra<sup>1</sup>, Rohit Kunar<sup>1</sup>, Lolitika Mandal<sup>2</sup>, Debasmita P Alone<sup>3</sup>, Shanti Chandrasekharan<sup>4</sup>, Anand  
3 Krishna Tiwari<sup>5</sup>, Ashim Mukherjee<sup>6</sup>, Madhu G Tapadia<sup>1</sup> and Jagat Kumar Roy<sup>1</sup>

4

5 <sup>1</sup>Cytogenetics Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University,  
6 Varanasi–221005, Uttar Pradesh, India

7 <sup>2</sup>Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Mohali,  
8 Manauli–140306, India

9 <sup>3</sup>School of Biological Sciences, National Institute of Science Education and Research (NISER) PO-  
10 Bhipur-Padanpur, Pin–752050, Odisha, India

11 <sup>4</sup>Division of Genetics, Indian Agricultural Research Institute (IARI), Pusa, New Delhi, Delhi–110012,  
12 India

13 <sup>5</sup>School of Biological Sciences and Biotechnology, Indian Institute of Advanced Research (IIAR),  
14 Gandhinagar–382007, Gujarat, India

15 <sup>6</sup>Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University,  
16 Varanasi–221005, Uttar Pradesh, India

17 **Abstract**

18 Mutants provide an excellent platform for the discovery and characterization of gene functions. The  
19 present communication is a pioneering treatise on a hitherto undescribed function of the gene coding for  
20 the mRNA decapping protein 2 (*DCP2*) in *Drosophila melanogaster*. *DCP2*, the gene coding for the  
21 mRNA decapping enzyme, has been studied in various model organisms in the light of maintenance of  
22 transcript abundance and stability but has never been implicated in tumorigenesis. Herein, we describe  
23 the mapping and characterization of a novel tumour suppressor allele of *DCP2* (*CG6169*), which we  
24 named as *lethal(3)tumorous brain [l(3)tb]*. The homozygous mutant individuals show prolonged larval  
25 life, develop larval brain tumors and are lethal in the larval/pupal stages. The tumour is characterized by  
26 the presence of increased number of superficial neuroblasts, abnormal chromosomal condensation and  
27 causes overgrowth in the wing and the eye-antennal discs of the homozygous mutant larvae, all of which  
28 are rescued by the introduction of a functional copy of *DCP2* in the mutant background, thereby  
29 establishing the causal role of the mutation and providing a genetic validation of the allelism. Our  
30 findings therefore ascribe a novel role of tumor suppression to *DCP2* besides its cognate function of  
31 mRNA decapping and thereby identify it as a potential candidate for future research on tumorigenesis.

## 32 **Introduction**

33 Tumorigenesis occurs either due to gain-of-function of an oncogene or loss-of-function of a tumor  
34 suppressor gene. As many as 57 oncogenes and 81 tumor suppressor genes have been identified through  
35 genome wide sequence studies apart from conventional approaches of various intragenic mutations  
36 (Vogelstien *et al.* 2013). Collective studies from developmental biology in the field of *Drosophila*, mouse  
37 and humans revealed that in most cases, the initiating event in the formation of a malignant tumor or  
38 neoplasia is a loss of function in the regulatory genes controlling cell growth and differentiation (Gateff  
39 and Schneiderman 1967, 1969; Harris *et al.* 1969; Knudson *et al.* 1971; Harris 2005; Papagiannouli and  
40 Mechler 2013). *Drosophila* shows classic hallmarks of cancer, such as evasion of apoptosis, sustained  
41 proliferation, metastasis, prolonged survival, genome instability and metabolic reprogramming (Luo *et al.*  
42 2009; Hanahan and Weinberg, 2011) and these phenotypes result from loss of function of a tumor  
43 suppressor gene in general, also called as recessive oncogenes (Mechler 1994).

44 In our present communication, we show the characterization of a new tumor suppressor mutation in  
45 *Drosophila melanogaster*, which was subsequently identified to be an allele of *Decapping protein 2*  
46 (*DCP2*; CG6169). The homozygous mutant individuals show prolonged larval life, develop larval brain  
47 tumors and are lethal in the larval/pupal stages. Hence, the mutation was initially named as  
48 *lethal(3)tumorous brain [l(3)tb]*. The tumor is characterized by the presence of increased number of  
49 superficial neuroblasts and abnormal chromosomal condensation. The mutation is also responsible for  
50 causing overgrowth in the wing and the eye-antennal discs of the homozygous mutant larvae.  
51 Recombination and complementation mapping of the mutation show that it is allelic to *Decapping protein*  
52 *2 (DCP2)* located at 72A1 on the left arm of chromosome 3. Complementation analyses of the mutation  
53 with alleles of *DCP2* show phenotypes similar to *l(3)tb* homozygotes, thereby confirming the proposed  
54 allelism. Over-expression of wild type *DCP2* in the mutant background rescues the mutant phenotypes,  
55 thereby providing a genetic validation of allelism. Molecular mapping identified the mutation to be  
56 residing in the 5'UTR coding region of *DCP2*. Our findings therefore ascribe a novel role of tumor

57 suppression to *DCP2* besides its cognate function of mRNA decapping and thereby identify it as a  
58 potential candidate for future research on tumorigenesis.

## 59 **Materials and Methods:**

### 60 **Fly strains and rearing conditions:**

61 Fly cultures were raised on standard food containing agar, maize powder, yeast, sugar and supplemented  
62 with anti-fungal (Nepagin, methyl-p-hydroxy benzoate) and anti-bacterial (propanoic acid) chemicals at  
63  $23\pm 1^\circ\text{C}$ . Subsequently genetic crosses were carried out following standard procedures. Oregon R+ was  
64 used as the wild type strain. The recessive *l(3)tb* mutation (*yw; +/+; l(3)tb /TM6B, Tb<sup>1</sup>, Hu, e<sup>1</sup>*) was  
65 isolated in a genetic screen and the mutation was maintained with the *TM6B* balancer which established  
66 its linkage to chromosome 3. The multiply marked “*rucuca*” (*ru h th st cu sr e ca/TM6B, Tb*) and  
67 “*ruPrica*” (*ru h th st cu sr e Pr ca/TM6B, Tb*) chromosomes were employed for recombination mapping  
68 (Lindsley and Zimm 1992). *w; Δ2 -3, Sb/TM6B, Tb<sup>1</sup>, Hu, e<sup>1</sup>* (Cooley *et al.* 1988) and *CyO, P{Tub-*  
69 *Pbac/T}2/Wg[Sp-1]; +/TM6B, Tb, Hu, e<sup>1</sup>* (Bloomington Stock No. 8586) were used for providing  
70 transposase source for *P* element and *piggyBac* specific transposable element, respectively, in  
71 mutagenesis experiment. Second chromosome balancer *Sp/CyO* (O’Donnell *et al.* 1975) and third  
72 chromosome balancer *yw; TM3, Sb, e<sup>1</sup> /TM6B, Tb<sup>1</sup>, Hu, e<sup>1</sup>* were obtained from Bloomington *Drosophila*  
73 stock center. The *elav-GAL4* (Lin and Goodman 1994), *y<sup>1</sup> w; P{Act5C-GAL4}25F01/CyO, y w; +/+;*  
74 *Tub-GAL4/ TM3, Sb, e* and *UAS-GFP* stocks were obtained from the Bloomington *Drosophila* Stock  
75 Center. Transgenic *UAS-DCP2 RNAi* (on chromosome 1 and chromosome 2 were obtained from Vienna  
76 *Drosophila* RNAi stock Centre, VDRC and *w; UAS-mCD8::GFP* (Lee and Luo, 1999) from Bloomington  
77 *Drosophila* stock center. The lethal insertion mutants of gene *Decapping protein2* -  
78 *PBac{RB}DCP2<sup>e00034</sup>/TM6B, Tb<sup>1</sup> Hu, e<sup>1</sup>* (Thibault *et al.* 2004) and *P{GT1}DCP2<sup>BG01766</sup>/TM3, Sb<sup>1</sup>, e<sup>1</sup>*  
79 (Lukacsovich *et al.* 2001) were obtained from Exelixis Stock Center, Harvard University and  
80 Bloomington *Drosophila* stock center, respectively.

81 Deficiency stock *Df(3L)RM96* was generated in the laboratory using progenitor *P* element stocks, viz.,  
82 *P{RS5}5-SZ-3486*, *P{RS5}5-SZ-3070*, *P{RS3}UM-8356-3*, *P{RS3}UM-8241-3*, *P{RS3}CB-0072-3*, *yw*  
83 *P{70FLP,ry<sup>+</sup>}3Fiso/y<sup>+</sup>Y;2iso;TM2/TM6C,Sb*, *w<sup>1118</sup>:iso/y<sup>+</sup>Y;2iso;TM2/TM6C,Sb*, obtained from Vienna  
84 *Drosophila* Resource Center (Golic and Golic, 1996; Ryder *et al.* 2007). Various deficiency stocks (Table  
85 S1, S2) and transposon insertion fly stocks (Table S3) used for complementation analysis were obtained  
86 from Bloomington *Drosophila* stock centre and Exelixis stock center.

### 87 **Analysis of lethal phase in *l(3)tb* homozygotes**

88 For analysis of lethal phase and morphological anomalies associated with the homozygous *l(3)tb*  
89 mutation, embryos were collected at the intervals of 2h on food filled Petri-plates. Embryos from wild  
90 type flies were collected as controls. The total number of eggs in each plate was counted and the embryos  
91 were allowed to grow at 23°C or 18°C or 16°C ( $\pm 1^\circ\text{C}$ ). Hatching of embryos and further development of  
92 larval stages was monitored to determine any developmental delay. Mutant larvae, at different stages,  
93 were dissected and the morphology of larval structures was examined.

### 94 **Meiotic recombination mapping of *l(3)tb* mutation**

95 Genetic recombination with multiple recessive chromosome marker *ru cu ca* was performed to map  
96 mutation in *yw: +/+; l(3)tb/TM6B*, *Tb* mutant in order to map the mutation. The *y w; l(3)tb/TM6B* males  
97 were crossed to virgin *+/+; ru Pri ca/TM6B* females to recover *l(3)tb* without *y w* on X-chromosome. The  
98 F1 *l(3)tb/TM6B* males were crossed to virgin *+/+; ru cu ca* females and the F2 progeny *+/+;*  
99 *l(3)tb/rucuca* virgin females were selected. Recombination of the *l(3)tb* and *rucuca* bearing chromosomes  
100 is expected to occur in these F2 flies. These F2 virgins were then crossed to *ru Pri ca/TM6B* males to  
101 score the frequency of recombinants in the F3 progeny. The *l(3)tb* phenotype cannot be scored in these  
102 flies because in F3, these flies carry *l(3)tb* mutation only in the heterozygous condition. Therefore, all the  
103 F3 progeny males obtained, were individually scored for *ru*, *h*, *th*, *st*, *cu*, *sr*, *e* and *ca* phenotypes and then

104 they were individually crossed with 2-3 virgin *l(3)tb/TM6B* females to identify which of them had the  
105 *l(3)tb* mutation along with other scored markers.

### 106 **Complementation mapping of the *l(3)tb* mutation**

107 Complementation analysis of the mutation in *l(3)tb* allele was carried out with Exelixis and DrosDel  
108 deficiency stocks spanning the entire chromosome 3 (Table S1). Virgin *y w; +/+; l(3)tb/TM6B, Tb*  
109 females were crossed with the males of the various deficiency stocks and the non-tubby F1males  
110 heterozygous for *l(3)tb* and the deficiency were observed carefully for the lethal phenotype. The lethal  
111 molecular lesion in *l(3)tb* was also checked for their allelic partners directly by complementation analysis  
112 using molecularly characterized lethal *P*-insertion alleles. 25 lethal *P*- insertion alleles were selected  
113 from the region narrowed down through recombination and deficiency mapping. Genetic crosses were set  
114 taking males from the lethal *P*-insertion and virgin females from the mutant *l(3)tb* fly stock. The non-  
115 tubby progeny, heterozygous for lethal *P*-insertion and lethal *l(3)tb* mutation were scored for the  
116 phenotype.

117 Reversion analysis was performed by the excision of *piggyBac* transposon in *DCP2<sup>e00034</sup>* with the help of  
118 *piggyBac* specific transposase source, *CyO, P{Tub-Pbac}2/Wg<sup>SP-1</sup>* (Thibault *et al.* 2004) and similarly by  
119 the excision of *P*-element in *DCP2<sup>BG01766</sup>* strain using  $\Delta 2-3, Sb/TM6B, Tb^1, Hu, e^1$  (Cooley *et al.* 1988)  
120 transposase source as ‘jumpstarter stock’, both obtained from Bloomington stock centre. Virgin flies from  
121 the mutator stocks *DCP2<sup>e00034</sup>* and *DCP2<sup>BG01766</sup>* strain were crossed to male flies from respective  
122 ‘jumpstarter stock’. F1 male flies with mosaic eye pigmentation carrying both the transposase and  
123 respective transposons were selected and crossed to JSK-3 (*TM3, Sb, e<sup>1</sup>/TM6B, Tb<sup>1</sup>, Hu, e<sup>1</sup>*) virgins and  
124 from the next generation rare white eyed revertant F2 flies were selected (Figure S9).

### 125 **Genomic DNA extraction, Primer Design and PCR**

126 Single Fly genomic DNA isolation for PCR was done as essentially described (Gloor and Engels 1992;  
127 Garozzo and Christensen 1994). Genomic DNA for polymerase chain reaction (PCR) was isolated by  
128 homogenizing 50 male flies from each of the desired genotype or 80-100 third instar larvae from  
129 homozygous mutant *l(3)tb* (Sambrook *et al.* 1989).

130 Primers were designed by using a modified version of the Primer3Plus. Sequence for the genomic region,  
131 narrowed down by the mapping strategies, was downloaded from the FlyBase (version R5). To analyze  
132 any molecular lesion in the DNA of homozygous *l(3)tb* mutant, 28 pairs of primers were designed for  
133 genomic region of gene *Decapping protein 2* (CG6169; 7.69 kbp) from 3L:15811834..15819523 (Table  
134 S5, S6, S7, S8) (Rozen and Skaletsky 2000).

135 Genomic DNA was subjected to PCR, with final volume of 25  $\mu$ l containing 25 pM each of the two  
136 primers, forward and reverse, for each primer pair, 200  $\mu$ M of each dNTP (New England Biolabs, USA)  
137 and 1.5U of *Taq* DNA Polymerase (New England Biolabs, USA). The cycling parameters included an  
138 initial denaturation of 5 min at 95<sup>0</sup>C followed by 30 cycles of denaturation at 94<sup>0</sup>C for 1 min, annealing  
139 (temperature accordingly to the specific primers for 1 min) and extension at 72<sup>0</sup>C for 1 min, with 10 min  
140 extension in the last cycle. PCR products were checked for amplification using 2% agarose gel along with  
141 100bp DNA ladder or the *pUC12* vector DNA digested with *Hinf*I as a molecular marker.

#### 142 **Automated Sequencing of PCR amplicons:**

143 The PCR products were sequenced directly with the help of Applied Biosystem 3130 Genetic Analyser  
144 platform, BBI, USA. The PCR products were eluted from 0.8% agarose gel using the gel-extraction kit  
145 (Fermentas Life Sciences, EU), following manufacturer's protocol and were processed by Applied  
146 Biosystems cycle sequencing kit version 3.1 using ready reaction (RR) mix and 10X PCR buffer in a 10  
147  $\mu$ l reaction volume and processed in both forward and reverse directions with the same set of primers  
148 employed for initial PCR. The fluorescently labeled DNA product was precipitated using ABI Big Dye  
149 Terminator Clean up method following manufacturer's recommendation and dissolved in Hi-Di

150 (Formamide) and processed for sequencing. The sequences were base-called and assembled using  
151 Geospiza FinchTV version 1.4 (<http://www.geospiza.com/Products/finchtv.shtml>). Homology search and  
152 alignments were performed using BLAST algorithm available at NCBI and FlyBase.

### 153 **RNA isolation and Reverse Transcription-PCR**

154 Total RNA was isolated from healthy wandering third instar larvae of wild type and delayed third instar  
155 larvae from homozygous *l(3)tb* mutant using TRIzol reagent following the manufacturer's recommended  
156 protocol (Sigma-Aldrich, India). The samples were incubated with 2U of RNase-free DNaseI (MBI  
157 fermentas, USA) for 30 minutes at 37°C to remove any residual DNA and dissolved in DEPC (Diethyl  
158 pyrocarbonate, Sigma, USA) treated water. First strand cDNA was synthesized using M-MuLV Reverse  
159 Transcriptase (RT) (Life Technologies, Invitrogen). Briefly, ~5 µg of total RNA using 20U of RNase  
160 OUT (Invitrogen), 80 pmol of oligo-dT<sub>18</sub> primer (New England Biolabs, USA), 500µM of dNTP mix and  
161 100U of M-MuLV reverse transcriptase (SuperScript III Reverse Transcriptase, Invitrogen) were added to  
162 a final reaction volume of 20µl followed by incubation for 1h at 37°C. The reverse transcriptase enzyme  
163 was inactivated at 65°C for 15 min. 1/20<sup>th</sup> (1µl) volume of the reaction mixture was subjected to second  
164 strand synthesis using the primer pair for the gene *DCP2* (3L:15814923-15815518) giving an amplicon  
165 size of 595 bp with genomic DNA (gDNA) and 539 bp with complementary DNA (cDNA). G3PDH  
166 (Glycerol 3 Phosphate dehydrogenase) was used as internal control. The specific primers used were:

167 Forward (DCP2): TATCAAATCCATGCCCGTTG and Reverse (DCP2):  
168 GTCACAGGAGTGC GAAATGA. Forward (G3PDH): 5'-CCACTGCCGAGGAGGTCAACTA-3';  
169 Reverse (G3PDH): 5'-GCTCAGGGTGATTGCGTATGCA-3'. The thermal cycling parameters included  
170 an initial denaturation at 94°C (4 min) followed by 30 cycles of 35 sec at 94°C, 30 sec at 60°C (For  
171 G3PDH), 40 sec at 54°C (for DCP2), 1 min at 72°C. Final extension was carried out at 72°C for 5 min.  
172 The PCR products were electrophoresed on a 2% agarose gel with appropriate molecular weight markers.

## 173 **Poly-acrylamide gel electrophoresis (PAGE) and Immunoblotting**

174 The larval brain ganglia of the desired genotypes were dissected out in PSS and homogenized in the  
175 protein sample buffer (100 mM Tris, pH 6.8; 1M DTT; 10% SDS; 100 mM phenylmethyl sulphonyl  
176 fluoride (PMSF), pH 6.8; 1% bromophenol blue and 1% glycerol). Protein samples were resolved in  
177 denaturing condition in 12% vertical SDS-polyacrylamide slab gel using a discontinuous buffer system  
178 (Laemmli 1970) and electrophoretically transferred to polyvinylidene fluoride membrane (PVDF,  
179 Millipore, USA) at 0.8mA/cm<sup>2</sup> or 50V through wet blotting apparatus (Biotech, India). The membrane  
180 was rinsed 2 times for 5 min each, in TBST (100 mM Tris, pH 7.4; 150 mM NaCl, 0.1% Tween 20) and  
181 blocked for 2 h at RT in blocking buffer (5% skimmed milk powder in TBST). The membrane was  
182 probed with primary antibody against Dlg (1:100) and detected with Anti mouse-HRP secondary antibody  
183 (dilution 1:2000) using enhanced chemiluminescence (ECL) detection as per manufacturer's instruction  
184 (SuperSignal, Pierce, USA). Membrane was incubated in 100 mM  $\beta$ -mercapto ethanol, 2% SDS, 62.5  
185 mM Tris, pH 6.8 at 50<sup>o</sup>C for 30 min and probed with anti  $\beta$ -tubulin antibody at 1:200 dilutions.

## 186 **Cytological techniques**

187 Mitotic chromosomes from brain ganglia of *l(3)tb* homozygous larvae of different ages (5<sup>th</sup> to 12<sup>th</sup> day  
188 after hatching) and from that of wild type late third instar larvae were prepared as per standard protocol  
189 (Lakhota *et al*, 1979). Brain ganglia from mutant larvae of different ages and wild type late third instar  
190 larvae were dissected in Poel's salt solution, incubated in 1% toluidine blue (pH 7) for 1h at 24<sup>o</sup>C, fixed in  
191 Bodain's fixative and then processed as mentioned by Truman and Bate (1988) to visualize and score the  
192 number of darkly stained superficial neuroblasts.

## 193 **Analysis of Eye morphology**

194 The fly was anaesthetized, and decapitated with a sharp blade or needle. The decapitated head was briefly  
195 dipped in a drop of transparent nail polish. The head was then placed on a clean, dry area of the same  
196 slide and the nail polish layer was allowed to dry at RT for 5-10 min. The dried layer of nail polish was



197 peeled off from the eye with the help of fine dissecting needles and was carefully placed on another clean  
198 glass slide with the imprint side facing up and flattened by gently placing a cover slip. The eye imprint  
199 was then examined under a microscope using 20X differential interference contrast (DIC) objective as  
200 described (Arya and Lakhotia 2006).

### 201 **BrdU incorporation studies to study replication profile of neuroblasts**

202 Brain ganglia from larvae of different age groups, i.e., 6 days ALH in case of wild type and 6 to 13 days  
203 ALH in case of *l(3)tb* homozygous larvae were dissected in Poels' salt solution, labeled with  
204 Bromodeoxy-Uridine (BrdU) Sigma, 20 $\mu$ M) at room temperature for 60 min in dark. They were then  
205 fixed in 90% ethanol for 30 min and passed through descending ethanol grades (15 min each), briefly  
206 hydrolyzed in 2N HCl for 15 min at room temperature, washed in PBS and incubated with 10% normal  
207 goat serum for 1 h at 4°C for blocking and incubated overnight with anti-BrdU antibody at 4°C. The  
208 bound anti-BrdU antibody was subsequently detected by anti-mouse IgG-FITC conjugate (Sigma, dilution  
209 1:64) under a fluorescence microscope after mounting the ganglia in antifade (Sigma).

### 210 **Immunostaining**

211 The imaginal discs and/or brain ganglia were collected from wild type *Oregon R*<sup>+</sup> wandering 3<sup>rd</sup> instar  
212 larvae, just before pupation (110 h, AEL) and in mutant homozygous *l(3)tb* from day 6 and day 10/12, as  
213 homozygous mutant larvae has delayed development up to 12-13 days. The tissues were processed for  
214 immunostaining with desired antibodies as described (Banerjee and Roy, 2017). For imaging endogenous  
215 GFP expression, tissues were dissected in 1X PBS and rinsed with 0.1% PBT. Counterstaining was  
216 performed with either DAPI (4', 6-diamidino-2-phenylindole dihydrochloride, Sigma) at 1 $\mu$ g/ml, or  
217 phalloidin-TRITC (Sigma-Aldrich, India) at 1:200 dilutions. Tissues were mounted in DABCO (antifade  
218 agent, Sigma). Samples were examined with Zeiss LSM 510 Meta laser scanning confocal microscope at  
219 appropriate settings using plan apo 20X, 40X or 63 X oil immersion objectives.

### 220 **Antibodies**

221 Primary antibodies used in this study were - Anti-Discs large, 4F3 (Dilution 1:50, Developmental Studies  
222 Hybridoma Bank, Iowa,USA), Anti-Armadillo (1:100, a kind gift by Prof LS Shashidhara, Pune, INDIA),  
223 Anti-Elav (Rat-Elav-7E8A10, Dilution 1:100, DSHB, USA), 22C10 (Dilution 1:100, DSHB, Iowa, USA),  
224 Anti-DE-Cadherin (DCAD2,Dilution 1:20, DSHB, Iowa, USA), Anti-phospho-Histone 3 (Dilution1:500,  
225 Millipore, Upstate, USA), Anti-Fasciclin II (1D4, Dilution 1:50, DSHB, Iowa, USA), Anti-Deadpan  
226 (Dilution 1:800, a kind gift from Prof. Volker Hartenstein, University of California, USA), Anti-repo  
227 (8D12, Dilution 1:10, DSHB, Iowa, USA ), and Anti- $\beta$ -tubulin (E7, Dilution 1;200, DSHB, Iowa, USA).  
228 Secondary antibodies used were Alexa Fluor 488 conjugated goat anti-mouse IgG, Alexa Fluor 488  
229 conjugated goat anti-rat IgG, Alexa Fluor 488 conjugated donkey anti-rabbit IgG and Alexa Fluor 488  
230 conjugated goat anti-guinea pig IgG from Molecular Probes, USA at a dilution of 1:200. Cy3 conjugated  
231 Anti-rabbit IgG and Cy3 conjugated Anti-mouse IgG (Sigma-Aldrich, India) were also used at 1:200  
232 dilutions, biotinylated anti-rabbit IgG (Vector Lab) and streptavidin conjugated HRP (Vector Lab) and  
233 Anti-mouse HRP (Bangalore Genie, India). The immunostained slides were observed under Zeiss LSM  
234 510 Meta Laser Scanning Confocal microscope, analysed with LSM softwares and assembled using  
235 Adobe Photoshop 7.0

## 236 **Statistical analysis**

237 Sigma Plot (version 11.0) software was used for statistical analyses. All percentage data were subjected to  
238 arcsine square-root transformation. For comparison between the control and experimental samples, One-  
239 Way ANOVA was performed. Data were expressed as mean  $\pm$  S.E. of mean (SEM) of several replicates.

## 240 **RESULTS**

241 ***l(3)tb* homozygotes show the classic hallmarks of cancer in *Drosophila* including developmental**  
242 **delay, abnormal karyotype, larval/pupal lethality alongwith tumorous brain and wing imaginal disc**  
243 Developmental analysis of *l(3)tb* homozygotes showed that while embryos hatched normally and  
244 developed alike their heterozygous siblings [*l(3)tb/TM6B*], the third instar larvae reached the wandering

245 stage quite late with the larval stage extending up to 12 or 13 days (**Figure 1B**). Only 66.8% of the larvae  
246 survived to pupate (**Table 1**), but died in the pupal stage following bloating, enhancement in size and  
247 cessation of growth (**Figure 1A**). Hence, the mutation is absolutely lethal with the lethality being  
248 pronounced in the pupal stage. Lowering the temperature to 16°C or 18°C reduced the larval mortality,  
249 causing 96% of larvae to pupate but did not improve pupal survival (**Figure 1 C and D**). Analysis of  
250 larval brain and imaginal discs in the homozygotes in the early (Day 6) and late (Day 10-12) larval phase  
251 showed gross morphological alterations in the size of the larval brain, wing and eye imaginal discs  
252 (**Figure 2A–G**) as compared to the wild type counterparts of similar developmental stage (115h ALH;  
253 After Larval Hatching). The brain was smaller in size than the wild type (*Oregon R*<sup>+</sup>) or heterozygous  
254 [*l(3)tb/TM6B*] individuals till 115 ALH but started showing aberrant growth in the dorsal lobes thereafter,  
255 showing significant differences in the diameter and area of the lobes. The overgrown brain hemispheres  
256 remained more or less symmetric in most of the cases, except in some where it got deformed and fused  
257 with the imaginal discs (**Figure 2 J and K**). A similar trend in morphological aberration was observed in  
258 the wing discs, which remained smaller initially but enlarged sufficiently later (**Figure 2L**), with  
259 abnormal protrusion in the wing pouch.

260 Analysis of mitotically active cell population by screening for the metaphase marker protein,  
261 phosphorylated histone H3 (PH3) revealed increased number of active mitoses in the mutant homozygous  
262 brains (**Figure 3A–O; 3V**) and wing discs (**Figure 3P–V**) (Day 6) in comparison to the wild type, the  
263 number of which increased with increase in larval age of the mutant. However, mitotic karyotypes of the  
264 mutant brain lacked numerical aberrations, despite showing extensive variability in condensation (**Figure**  
265 **2 H and I**).

266

### 267 **The mutation *l(3)tb* alters expression of DE-cadherin in brain and wing imaginal discs and affects** 268 **neuronal number and fasciculation**

269 During the onset and progression of tumorigenesis, the mutation was observed to impart numerous  
270 perturbations in the developmental expression of essential molecules globally. DE-cadherin, a protein

271 expressed in the adherens junctions besides being instrumental in neural development, was found to show  
272 altered expression in the homozygous mutant brain and wing imaginal discs in the late larval stages (Day  
273 10) (**Figure 4D**). The wild type brain (Day 5; 115h ALH) however, showed strong expression in the  
274 neuropile and in the Outer and Inner Proliferating centres (OPC and IPC, respectively) of the brain  
275 hemispheres (**Figure 4A**). The central brain in *Drosophila* harbors the Mushroom Body (MB) and other  
276 neurons, which express the cell adhesion molecule Fasciclin II, which also labels the pioneering axonal  
277 tracts or fascicles in the neuropile and axonal projections in the ventral ganglion (**Figure 4B**). Mature  
278 mutant larvae showed disrupted arrangement of neurons of the MB and those of the central brain (**Figure**  
279 **4E**). Expression analysis of the pan-neuronal marker, Elav showed a progressive decrease with increase in  
280 larval age and simultaneous maturation of the tumor (**Figure 6A, D and G**), implying progressive loss of  
281 neurons during the progression of tumorigenesis. Discs-large (Dlg), a septate junction marker, which is  
282 strongly expressed in the central brain as well as in the neurons and their projections emanating from the  
283 ventral nerve cord (VNC) (**Figure 6B**), showed enhanced expression in mature mutant larval brain (Day  
284 10) as compared to early third instar larval brain (both wild type or mutant) but its pattern in the central  
285 brain and neuropile was lost (**Figure 6E and H**). The staining pattern is in agreement with results  
286 obtained from immunoblotting experiments (**Figure 6V**). Parallel to the disruption of DE-cadherin in the  
287 wing disc (**Figure 5E and I**), a progressive disruption of Armadillo, the *Drosophila* homologue of  $\beta$ -  
288 catenin and is associated with the E-cadherin junctions, was observed in the late/mature mutant larvae  
289 (**Figure 5F and J**). Closer analysis revealed that the tumorous wing disc showed enlarged cell sizes  
290 (**Figure 5Q**) as compared to the wild type (**Figure 5M**) or early stage tumor tissue and that these two  
291 proteins are co-expressed in the wing pouch (**Figure 5P**) but following the onset of tumorigenesis, the  
292 loss of armadillo occurs prior to that of DE-cadherin (**Figure 5T**).

293

294 **Eye-antennal discs and leg imaginal discs also show morphological and developmental anomalies in**  
295 ***l(3)tb* homozygous individuals**

296 Global analysis of morphological aberrations in the mutant homozygotes showed that besides the  
297 tumorous brain and wing imaginal discs, eye-antennal discs and leg imaginal discs were also overgrown  
298 with a transparent appearance. Expression of Elav and Dlg in the eye-antennal discs revealed similarities  
299 to the developmental perturbations observed in the wing discs and brain. In the early third instar mutant  
300 larvae (Day 6), all photoreceptor cells showed expression of Elav, similar to the wild type tissue (**Figure**  
301 **6J and N**). However, during advanced stages of larval tumorigenesis (Day 10), it dwindled eventually  
302 (**Figure 6R**). The Elav expressing cells which are posterior to the morphogenetic furrow co-express Dlg  
303 and demonstrate the typical ommatidial arrangement. In the mature mutant larvae however, the eye discs  
304 demonstrate significant deviations from the normal regular arrangement of ommatidia.

305 The leg imaginal discs, which reside in close proximity to the brain and wing imaginal discs also show  
306 enlargement in size which increases with advancement and retention of larval stage. They show gradual  
307 disruption of normal expression of DE-cadherin and Armadillo, alike tumorous wing discs (see above),  
308 implying the mutation and subsequent tumor to affect developmental homeostasis in adjacent tissues as  
309 well.

310

311 **Analysis of Meiotic Recombination and complementation mapping identify *l(3)tb* to be allelic to**  
312 ***DGP2*.**

313 The mutation *l(3)tb* was maintained with *TM6B* balancer, which established its localization on the third  
314 chromosome. Analysis of meiotic recombination frequencies of an unmapped mutation with known  
315 markers is a classical technique that has been routinely employed to identify its cytogenetic position.  
316 *Drosophila* has the advantage of having classical markers with well documented visible phenotypes for  
317 each chromosome, which aid in such mapping endeavours. In order to bring *l(3)tb* in a chromosome with  
318 such markers (*rucuca*), we allowed meiotic recombination to occur between *l(3)tb* and the 8 recessive  
319 markers present on the *rucuca* chromosome (**Table 2**). 113 recombinant males were observed and  
320 recombination frequencies were calculated in centiMorgan (cM). **Table 3** shows the recombination  
321 frequencies of each marker (locus) with the mutation *l(3)tb*. Preliminary analysis suggested that *l(3)tb*

322 was close to *thread* (*th*) with minimum recombination events between the two loci (2.65%). Further  
323 analysis of recombination events between *h-l(3)tb* [17.78%], *st-l(3)tb* [1.23%] and *cu-l(3)tb* [8.29%]  
324 (**Table 4**) and comparing with the positions of each of the markers, the mutation was estimated to be  
325 located left of *thread* (43.2 cM; band 72D1) between 41.71 cM–42.77 cM, *i.e.*, in the cytological position  
326 71F4-F5.

327 Complementation analysis with molecularly defined Drosdel and Exelixis deficiency lines (N=85),  
328 spanning the entire chromosome 3, identified four lines which failed to complement the mutation, *viz.*,  
329 *Df(3L)BSC774*, *Df(3L)BSC575*, *Df(3L)BSC845* and *Df(3L)RM95*, which was generated in the lab using  
330 progenitor RS stocks. Trans-heterozygotes *l(3)tb/Df(3L)BSC575* were pupal lethal and the dying non-  
331 tubby larvae showed phenotypes similar to *l(3)tb* homozygotes, suggesting the mutation to reside between  
332 71F1 and 72A1 on the left arm of chromosome 3. Further analysis using six deletion lines belonging to  
333 the above region (71F1–72A2) identified the mutation to reside between 71F4 to 71F5, which strangely is  
334 a gene desert region. Complementation analyses performed with lethal insertion alleles (N=26) of genes  
335 residing proximal or distal to 71F4-F5 identified two lethal *P*-element insertion alleles of *DCP2* (mRNA  
336 decapping protein 2; CG6169), *viz.*, *P{GTI}Dcp2<sup>BG01766</sup>* and *PBac{RB}Dcp2<sup>e00034</sup>*, which failed to  
337 complement the mutation *l(3)tb* (**Figure 7A and C**) as well as those deletions which had failed to  
338 complement *l(3)tb*, implying the mutation to be allelic to *DCP2* (72A1).

339

#### 340 **Trans-heterozygotes of *DCP2* mutants and *l(3)tb* show developmental delay, tumorous larval brain** 341 **with elevated neuroblast numbers, larval/pupal lethality and developmental defects in escapee flies**

342 Trans-heterozygotes of *l(3)tb* with either allele of *DCP2*, *viz.*, *P{GTI}Dcp2<sup>BG01766</sup>* and  
343 *PBac{RB}Dcp2<sup>e00034</sup>*, showed developmental delay. In either case, trans-heterozygous third instar larvae  
344 showed persistence of larval stage till Day 10 ALH (**Figure 7B and D**), and show tumorous phenotypes  
345 of brain and wing imaginal discs (data not shown), similar to the *l(3)tb* homozygotes. Expression pattern  
346 of Deadpan (Dpn), a marker for neuroblasts show increased number of neuroblasts in the larval brain of  
347 the trans-heterozygotes as well as *l(3)tb* homozygotes (**Figure 8F, K and P**). Also, the trans-

348 heterozygous progeny showed a higher mitotic index as compared to the wild type progeny, similar to  
349 *l(3)tb* homozygotes (**Figure 8G, L and P**). While *PBac{RB}Dcp2<sup>e00034</sup>/l(3)tb* was found to be 100%  
350 pupal lethal, *P{GTI}Dcp2<sup>BG01766</sup>/l(3)tb* was only 81.6% lethal (**Figure 7A and B**), with the rest 18.4%  
351 pupae eclosing as flies. However, the escapee flies showed several developmental abnormalities, *viz.*,  
352 defects in wing (9.5%), thorax closure (3.2%), loss of abdominal para-segments and abdominal bristles  
353 (3.2%), and presence of melanotic patches (22.2%), leg defects (41.3%) or eclosion defects (12.7%).  
354 Analysis of compound eyes in these escapees revealed complete loss of regular arrangement of ommatidia  
355 and ommatidial bristles. Abnormal external genitalia were also observed in the male escapees.  
356 Subsequent analysis of fertility showed that the trans-heterozygous escapee flies had compromised  
357 fertility with only 40% of the males and 21.7% of the females being fertile (**Table 5**).  
358 The similarity in the pattern of development and the defects associated with it between the *l(3)tb* trans-  
359 heterozygotes and homozygotes provide a strong genetic proof of allelism between *l(3)tb* and *DCP2*.

360

### 361 **A single nucleotide mutation in the promoter region affects transcription of *DCP2* in *l(3)tb* mutants**

362 To identify the sequence alterations in *DCP2* in the *l(3)tb* homozygotes, 28 pairs of overlapping primers  
363 were designed, spanning the entire gene (7.689 kb). **Figure 9** shows the four mutations identified,  
364 *viz.*, **G(3L:15819202)A**, **G(3L:15819384)A**, **C(3L:15819446)T** and **C(3L:15819691)A**, out of which  
365 **C(3L:15819691)A** resides in the promoter *DCP2\_1* (Eukaryotic Promoter Database; EPD, SIB) (**Figure**  
366 **9E**). *DCP2* codes for four transcripts, *viz.*, *DCP2-RA*, *RB*, *RD* and *RE*. All transcripts differ in their 5'  
367 and 3' UTRs but have conserved exon sequences. Analysis of gene expression using primers designed to  
368 amplify the exon common to all the transcripts showed absence of amplification (**Figure 9F**), implying  
369 the mutations identified above to affect gene transcription.

370

### 371 **Global overexpression of *DCP2* rescues mutant phenotypes associated with *l(3)tb***

372 Global over-expression of *DCP2* using ubiquitous GAL4 drivers (*Act5C-GAL4* or *Tub-GAL4*) in the  
373 mutant homozygous *l(3)tb* individuals rescued the larval and pupal lethality. **Table 6** shows the genotype

374 and fate of the progeny as scored from the rescue experiment. As can be seen, for over-expression of  
375 *DCP2* using *Act5C-GAL4*, out of 35.1% (N=155) non-tubby progeny (*l(3)tb* homozygous background),  
376 *i.e.*, *Act5C-GAL4/CyO* or *Sp; l(3)tb:UAS-DCP2/l(3)tb*, 21.3% (N=94) and 13.8% (N=61) segregated as  
377 curly (*Act5C-GAL4/CyO; l(3)tb:UAS-DCP2/l(3)tb*) and non-curly (or with sternopleural bristles: *Act5C-*  
378 *GAL4/Sp; l(3)tb:UAS-DCP2/l(3)tb*), respectively. Similarly, while over-expressing using *Tub-GAL4*, we  
379 obtained 37% (N=166) non-tubby progeny, *i.e.*, *UAS-DCP2/CyO* or *Sp; l(3)tb:Tub-GAL4/l(3)tb*, out of  
380 which, 17.2% (N=77) were curly (*UAS-DCP2/CyO; l(3)tb:Tub-GAL4/l(3)tb*) while 19.8% (N=89) were  
381 non-curly (*UAS-DCP2/ Sp; l(3)tb:Tub-GAL4/l(3)tb*).

382 In both the cases of overexpression, all non-tubby progeny pupated, devoid of any developmental  
383 anomalies reminiscent of *l(3)tb* mutation and emerged as flies. Thus, the rescue of the mutant phenotypes  
384 observed in *l(3)tb* homozygotes by global overexpression of *DCP2* iteratively substantiates the fact the  
385 *l(3)tb* is an allele of *DCP2* and that the tumor is caused solely owing to the loss of expression of *DCP2*.

## 386 Discussion

387 Mutants provide an excellent platform for exploration of gene function. In the present communication, we  
388 have mapped and characterized the phenotype of a novel mutation, *lethal(3)tumorous brain* [*l(3)tb*],  
389 which was found to allelic to *DCP2*, the mRNA decapping protein 2 in *Drosophila melanogaster*. Like  
390 other well established tumor suppressor mutants in *Drosophila*, *viz.*, *lethal(2) giant larvae* [*l(2)gl*], discs-  
391 large [*Dlg*] and *Scribble* [*Scrib*], *l(3)tb* homozygous embryos progress into and through the larval stages,  
392 grow normally until the third instar larval stage, undergo an extended larval life unlike normal  
393 individuals, pupate and then die. During the extended larval period, the larvae become bloated,  
394 transparent and the proliferating imaginal disc epithelia and nervous system appear dramatically aberrant.  
395 All these phenotypes are shared by most of the tumor suppressor mutants in *Drosophila*. The mitotic  
396 chromosomes in *l(3)tb* mutant show extended chromosomes albeit without any numerical anomaly. These  
397 secondary chromosomal changes also occur during the course of mammalian tumor progression and have  
398 some role in conferring metastatic potential to the tumor tissue (Yunis, 1983). In many tumors, cell cycle



399 is not dramatically altered but cells fail to respond to arrest cues and cause over-proliferation. In  
400 *Drosophila*, the overall size of the tissue rather than number of cells *per se* is regulated precisely  
401 (Johnston and Gallant, 2002). Woods and Bryant reported (Woods and Bryant, 1989) that in neoplastic  
402 tumors, cell sizes are smaller initially but maintain their proliferative state during the prolonged larval  
403 phase which grossly alters the morphology of the imaginal discs. The *l(3)tb* mutants, both homozygotes  
404 and heterozygotes with *DCP2* mutants showed a similar behavior along with a high mitotic index as  
405 evidenced by PH3 staining, and thus the overgrowth in the discs can be ascribed to failure of the cells to  
406 exit the precisely coordinated developmental cell cycles. Although the number of neuroblasts in these  
407 mutants was pronounced, as revealed by the expression of Deadpan and PH3, the expression of Elav  
408 showed that the number of neurons was reduced, which may be attributed to the arrest of terminal  
409 differentiation from neuroblasts to neurons and/or glia, similar to that observed in *brat* mutants (Bello et  
410 al, 2006; Betschinger et al, 2006). Elav is a transcription factor and regulates the expression of certain  
411 neuronal genes, one of the target genes being *Armadillo*, the *Drosophila* homologue of  $\beta$ -catenin.  
412 Armadillo is expressed in the adherens junctions along with DE-cadherin, while Dlg is expressed at the  
413 septate junctions. The altered profile of Armadillo, DE-cadherin and Dlg and the simultaneous loss of  
414 Elav in the later larval stages in the *l(3)tb* mutants may be due to disassembly of the adherens junctions  
415 (Cox et al, 1996) thereby affecting cell-cell adhesion between glial and neuronal bodies in the brain and in  
416 the over-proliferative cells of the wing imaginal disc. There exists an inverse relation between E-cadherin  
417 function and tumor progression (Derksen et al, 2006) as E-cadherin plausibly regulates  $\beta$ -catenin  
418 signaling in the Wnt pathway with a potential to inhibit mitogenic signaling through growth factor  
419 receptors. This facet of *l(3)tb* tumors is similar to the simultaneous loss of E-cadherin and  $\beta$ -catenin  
420 observed in advanced stages in majority of mammalian tumors (Christofori and Semb, 1999; Weinberg  
421 and Hanahan, 2000).

422 Identification of cytogenetic location of mutations is best performed by calculation of recombination  
423 frequencies between the unknown mutation and the position of known loci (Sturtevant, 1913), and hence,

424 recombination mapping, complementation analyses with regional deficiencies and duplications (Bridges,  
425 1917 & 1919; Muller, 1935; Cook et al, 2012) was performed which revealed that the mutation resides  
426 close to the *thread* locus (43.2 cM, 72D1) between 71F4-F5, a gene desert area on the left arm of  
427 chromosome 3. Further complementation analysis with genes downstream to the region identified the  
428 failure of *DCP2* (CG6169) mutants, viz., *DCP2*<sup>BG01766</sup> and *DCP2*<sup>e00034</sup>, to complement the mutation as well  
429 as show phenotypes similar to *l(3)tb* homozygotes, thereby establishing the allelic relationship of *l(3)tb* to  
430 *DCP2*. *DCP2* is located at 72A1, which is adjacent to the region identified, i.e., 71F4-F5, and is thus in  
431 agreement with the results obtained from recombination and/or deficiency mapping.

432 The eukaryotic promoter database identifies 2 promoters for *DCP2*, *DCP2\_1* and *DCP2\_2*. Sequencing  
433 analysis revealed a single transversion **C(15819691)A** in the promoter, *DCP2\_1*, which is expected to  
434 affect its transcription and the subsequent expression of the gene, which is clearly observed in expression  
435 analysis of *DCP2* in *l(3)tb* homozygotes. The alleles themselves are embryonic lethal when homozygous,  
436 but trans-heterozygotes, *l(3)tb/DCP2*<sup>e00034</sup> and *l(3)tb/DCP2*<sup>BG01766</sup> show morphological, physical and  
437 physiological phenotypes similar to *l(3)tb* homozygotes. These trans-heterozygotes were tumorous with  
438 prolonged larval life, show increase in neuroblast population, elevated mitoses, and pupal lethality, all of  
439 which are exemplified by *l(3)tb* homozygotes. Parallely, all these phenotypes were rescued by global  
440 over-expression of *DCP2* in the *l(3)tb* homozygous mutant background, thereby validating the allelism  
441 between *DCP2* and the mutation *l(3)tb* and hence, we refer to the mutant line as an established *loss-of-*  
442 *function* allele of *DCP2* with defined genetic and molecular bases of allelism, *DCP2*<sup>*l(3)tb*</sup>. The cognate  
443 function of *DCP2* is removal of the 7-methylguanosine cap from the 5' end of mRNAs, exposing them to  
444 the exonuclease, XRNI (Pacman) for degradation. In *Drosophila*, *DCP2* is the only decapping enzyme  
445 present and thus is extremely important for a number of growth processes throughout development. In  
446 other organisms as well, it is extremely conserved and has fundamentally important roles in development  
447 (Xu et al, 2006; Ma et al, 2013), DNA replication (Mullen and Marzluff, 2008; Schmidt et al, 2011),  
448 stress response (Hilgers et al, 2006; Xu and Chua, 2012), synapse plasticity (Hillebrand et al, 2010),

449 retrotransposition (Dutko et al, 2010) and viral replication (Hopkins et al, 2013). In *Arabidopsis*, *DCP2*  
450 loss-of-function alleles show accumulation of capped mRNA intermediates, lethality of seedlings and  
451 defects in post-embryonic development, with no leaves, stunted roots with swollen root hairs, chlorotic  
452 cotyledons and swollen hypocotyls (Goeres et al, 2007; Iwasaki et al, 2007; Xu et al, 2006). In humans as  
453 well, 5q21-22, the region harboring *DCP2* is frequently deleted in lung cancer (Hosoe et al, 1994;  
454 Mendes-da-Silva et al, 2000), colorectal cancer (Ashton-Richardt et al, 1989; Delattre et al, 1989) and  
455 oral squamous cell carcinoma (Mao et al, 1998). Cancer progression is associated with hyperactivated  
456 rRNA biogenesis (Chem et al 2011, Hein et al 2013) owing to the increased size and number of nucleoli  
457 (Pianese, 1896). Recently, Gaviraghi and coworkers (2018) have provided a plausible mechanism of  
458 regulation of aberrant rRNA biogenesis and/or maturation wherein the tumor suppressor PNR1 recruits  
459 the decapping complex (DCP1/2) to the nucleolus and modulates the synthesis and maturation of U3 and  
460 U8 rRNAs. Hence, *DCP2* has an unexplored role in development and/or tumorigenesis throughout phyla,  
461 which needs to be investigated. Ren and coworkers reported that *DCP2* is expressed in the adult  
462 *Drosophila* brain (Ren et al, 2012). The pronounced defects observed in *l(3)tb* homozygotes also pertain  
463 to the brain and wing disc. Hence, the loss of *DCP2* in these tissues may affect the developmental  
464 homeostasis existing in the gene expression network and may lead to tumorigenesis. We speculate that  
465 *DCP2* is potent enough to regulate the highly dynamic gene expression modules by virtue of its  
466 pioneering role in the mRNA decay pathways. Since the physiology of an organism is tightly regulated by  
467 the optimized titres of gene expression programs, a global loss of *DCP2* may lead to perturbed mRNA  
468 titres which in turn may alter the cellular response to such dismal conditions and eventually lead to drastic  
469 physiological disorders such as tumorigenesis. Although we are unsure of the exact mechanism(s) by  
470 which loss of *DCP2* leads to tumorigenesis, our findings in the allele, *DCP2<sup>l(3)tb</sup>*, propose an absolutely  
471 novel role of *DCP2* in tumorigenesis and identify *DCP2* as a candidate for future explorations of  
472 tumorigenesis.

473


474 **References**

- 475 Arya, R. and Lakhota, S.C., 2006. A simple nail polish imprint technique for examination of external  
476 morphology of *Drosophila* eyes. *Current science*, 90(9), pp.1179-1180.
- 477 Banerjee, A. and Roy, J.K., 2017. Dicer-1 regulates proliferative potential of *Drosophila* larval neural  
478 stem cells through bantam miRNA based down-regulation of the G1/S inhibitor Dacapo. *Developmental*  
479 *biology*, 423(1), pp.57-65.
- 480 Bello, B., Reichert, H. and Hirth, F., 2006. The brain tumor gene negatively regulates neural progenitor  
481 cell proliferation in the larval central brain of *Drosophila*. *Development*, 133(14), pp.2639-2648.
- 482 Betschinger, J., Mechtler, K. and Knoblich, J.A., 2006. Asymmetric segregation of the tumor suppressor  
483 brat regulates self-renewal in *Drosophila* neural stem cells. *Cell*, 124(6), pp.1241-1253.
- 484 Bridges, C.B., 1917. Deficiency. *Genetics*, 2(5), p.445.
- 485 Bridges, C.B., 1919. Specific modifiers of eosin eye color in *Drosophila melanogaster*. *Journal of*  
486 *Experimental Zoology*, 28(3), pp.337-384.
- 487 Christofori, G. and Semb, H., 1999. The role of the cell-adhesion molecule E-cadherin as a tumour-  
488 suppressor gene. *Trends in biochemical sciences*, 24(2), pp.73-76.
- 489 Cook, R.K., Christensen, S.J., Deal, J.A., Coburn, R.A., Deal, M.E., Gresens, J.M., Kaufman, T.C. and  
490 Cook, K.R., 2012. The generation of chromosomal deletions to provide extensive coverage and  
491 subdivision of the *Drosophila melanogaster* genome. *Genome biology*, 13(3), p.R21.
- 492 Cooley, L., Kelley, R. and Spradling, A., 1988. Insertional mutagenesis of the *Drosophila* genome with  
493 single P elements. *Science*, 239(4844), pp.1121-1128.
- 494 Cox, R.T., Kirkpatrick, C. and Peifer, M., 1996. Armadillo is required for adherens junction assembly,  
495 cell polarity, and morphogenesis during *Drosophila* embryogenesis. *The Journal of Cell Biology*, 134(1),  
496 pp.133-148.
- 497 Derksen, P.W., Liu, X., Saridin, F., van der Gulden, H., Zevenhoven, J., Evers, B., van Beijnum, J.R.,  
498 Griffioen, A.W., Vink, J., Krimpenfort, P. and Peterse, J.L., 2006. Somatic inactivation of E-cadherin and  
499 p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and  
500 angiogenesis. *Cancer cell*, 10(5), pp.437-449.
- 501 Dutko, J.A., Kenny, A.E., Gamache, E.R. and Curcio, M.J., 2010. 5' to 3' mRNA decay factors colocalize  
502 with Ty1 gag and human APOBEC3G and promote Ty1 retrotransposition. *Journal of virology*, 84(10),  
503 pp.5052-5066.
- 504 Fearon, E.R. and Vogelstein, B., 1990. A genetic model for colorectal tumorigenesis. *cell*, 61(5), pp.759-  
505 767.
- 506 Gateff, E. and Schneiderman, H.A., 1967, January. Developmental studies of a new mutant of *Drosophila*  
507 *melanogaster*-lethal malignant brain tumor (1 (2) GL4). In *American Zoologist* (Vol. 7, No. 4, pp. 760-+).

- 508 1313 DOLLEY MADISON BLVD, NO 402, MCLEAN, VA 22101 USA: SOC INTEGRATIVE  
509 COMPARATIVE BIOLOGY.
- 510 Gateff, E. and Schneiderman, H.A., 1969. Neoplasms in mutant and cultured wild-type tissues of  
511 *Drosophila*. *National Cancer Institute Monograph*, 31, pp.365-397.
- 512 Gaviraghi, M., Vivori, C., Sanchez, Y.P., Invernizzi, F., Cattaneo, A., Santoliquido, B.M., Frenquelli, M.,  
513 Segalla, S., Bachi, A., Doglioni, C. and Pelechano, V., 2018. Tumor suppressor PNR1 blocks rRNA  
514 maturation by recruiting the decapping complex to the nucleolus. *The EMBO journal*, 37(23), p.e99179.
- 515 Goeres, D.C., Van Norman, J.M., Zhang, W., Fauver, N.A., Spencer, M.L. and Sieburth, L.E., 2007.  
516 Components of the Arabidopsis mRNA decapping complex are required for early seedling  
517 development. *The Plant Cell*, 19(5), pp.1549-1564.
- 518 Golic, K.G. and Golic, M.M., 1996. Engineering the *Drosophila* genome: chromosome rearrangements  
519 by design. *Genetics*, 144(4), pp.1693-1711.
- 520 Hanahan, D. and Weinberg, R.A., 2000. The hallmarks of cancer. *cell*, 100(1), pp.57-70.
- 521 Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. *cell*, 144(5), pp.646-  
522 674.
- 523 Harris, H., 2005. A long view of fashions in cancer research. *Bioessays*, 27(8), pp.833-838.
- 524 Harris, H., Miller, O.J., Klein, G., Worst, P. and Tachibana, T., 1969. Suppression of malignancy by cell  
525 fusion. *Nature*, 223(5204), p.363.
- 526 Hein, N., Hannan, K.M., George, A.J., Sanij, E. and Hannan, R.D., 2013. The nucleolus: an emerging  
527 target for cancer therapy. *Trends in molecular medicine*, 19(11), pp.643-654.
- 528 Hilgers, V., Teixeira, D. and Parker, R., 2006. Translation-independent inhibition of mRNA  
529 deadenylation during stress in *Saccharomyces cerevisiae*. *Rna*, 12(10), pp.1835-1845.
- 530 Hillebrand, J., Pan, K., Kokaram, A., Barbee, S., Parker, R. and Ramaswami, M., 2010. The Me31B  
531 DEAD-box helicase localizes to postsynaptic foci and regulates expression of a CaMKII reporter mRNA  
532 in dendrites of *Drosophila* olfactory projection neurons. *Frontiers in neural circuits*, 4, p.121.
- 533 Hopkins, K.C., McLane, L.M., Maqbool, T., Panda, D., Gordesky-Gold, B. and Cherry, S., 2013. A  
534 genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the  
535 pools of Dcp2-accessible targets for cap-snatching. *Genes & development*, 27(13), pp.1511-1525.
- 536 Hosoe, S., Ueno, K., Shigedo, Y., Tachibana, I., Osaki, T., Kumagai, T., Tanio, Y., Kawase, I.,  
537 Nakamura, Y. and Kishimoto, T., 1994. A frequent deletion of chromosome 5q21 in advanced small cell  
538 and non-small cell carcinoma of the lung. *Cancer research*, 54(7), pp.1787-1790.
- 539 Iwasaki, S., Takeda, A., Motose, H. and Watanabe, Y., 2007. Characterization of Arabidopsis decapping  
540 proteins AtDCP1 and AtDCP2, which are essential for post-embryonic development. *FEBS*  
541 *letters*, 581(13), pp.2455-2459.

- 542 Johnston, L.A. and Gallant, P., 2002. Control of growth and organ size in *Drosophila*. *Bioessays*, 24(1),  
543 pp.54-64.
- 544 Knudson, A.G., 1971. Mutation and cancer: statistical study of retinoblastoma. *Proceedings of the*  
545 *National Academy of Sciences*, 68(4), pp.820-823.
- 546 Lakhotia, S.C., Roy, J.K. and Kumar, M., 1979. A study of heterochromatin in *Drosophila nasuta* by the  
547 5-bromodeoxyuridine-Giemsa staining technique. *Chromosoma*, 72(2), pp.249-255.
- 548 Lee, T. and Luo, L., 1999. Mosaic analysis with a repressible cell marker for studies of gene function in  
549 neuronal morphogenesis. *Neuron*, 22(3), pp.451-461.
- 550 Lin, D.M. and Goodman, C.S., 1994. Ectopic and increased expression of Fasciclin II alters motoneuron  
551 growth cone guidance. *Neuron*, 13(3), pp.507-523.
- 552 Lindsley, D.L. and Zimm, G.G., 1992. The genome of *Drosophila melanogaster*, p.1100.
- 553 Lukacsovich, T., Asztalos, Z., Awano, W., Baba, K., Kondo, S., Niwa, S. and Yamamoto, D., 2001. Dual-  
554 tagging gene trap of novel genes in *Drosophila melanogaster*. *Genetics*, 157(2), pp.727-742.
- 555 Luo, J., Solimini, N.L. and Elledge, S.J., 2009. Principles of cancer therapy: oncogene and non-oncogene  
556 addiction. *Cell*, 136(5), pp.823-837.
- 557 Ma, J., Flemr, M., Strnad, H., Svoboda, P. and Schultz, R.M., 2013. Maternally recruited DCP1A and  
558 DCP2 contribute to messenger RNA degradation during oocyte maturation and genome activation in  
559 mouse. *Biology of reproduction*, 88(1), pp.11-1.
- 560 Mao, E.J., Schwartz, S.M., Daling, J.R. and Beckmann, A.M., 1998. Loss of heterozygosity at 5q 21–22  
561 (adenomatous polyposis coli gene region) in oral squamous cell carcinoma is common and correlated with  
562 advanced disease. *Journal of oral pathology & medicine*, 27(7), pp.297-302.
- 563 Mechler B.M. 1994. Gordon S, editor. The Legacy of Cell Fusion. Oxford University Press. Ch. 13, p  
564 183–198.
- 565 Mendes-da-Silva, P., Moreira, A., Duro-da-Costa, J., Matias, D. and Monteiro, C., 2000. Frequent loss of  
566 heterozygosity on chromosome 5 in non-small cell lung carcinoma. *Molecular pathology*, 53(4), p.184.
- 567 Mullen, T.E. and Marzluff, W.F., 2008. Degradation of histone mRNA requires oligouridylation followed  
568 by decapping and simultaneous degradation of the mRNA both to 3' and 3' to 5'. *Genes &*  
569 *development*, 22(1), pp.50-65.
- 570 Muller, H.J., 1935. The origination of chromatin deficiencies as minute deletions subject to insertion  
571 elsewhere. *Genetica*, 17(3), pp.237-252.
- 572 Papagiannouli, F. and Mechler, B.M., 2013. Modeling tumorigenesis in *Drosophila*: current advances and  
573 future perspectives. In *Future aspects of tumor suppressor gene*. InTech.
- 574 Pianese, G., 1896. *Beitrag zur histologie und aetiologie des carcinoms* (Vol. 1). G. Fischer.


- 575 Praz, V., Perier, R., Bonnard, C. and Bucher, P., 2002. The Eukaryotic Promoter Database, EPD: new  
576 entry types and links to gene expression data. *Nucleic Acids Research*, 30(1), pp.322-324.
- 577 Ren, J., Sun, J., Zhang, Y., Liu, T., Ren, Q., Li, Y. and Guo, A., 2012. Down-regulation of Decapping  
578 Protein 2 mediates chronic nicotine exposure-induced locomotor hyperactivity in *Drosophila*. *PLoS*  
579 *one*, 7(12), p.e52521.
- 580 Rozen, S. and Skaletsky, H., 2000. Primer3 on the WWW for general users and for biologist  
581 programmers. In *Bioinformatics methods and protocols* (pp. 365-386). Humana Press, Totowa, NJ.
- 582 Ryder, E., Ashburner, M., Bautista-Llacer, R., Drummond, J., Webster, J., Johnson, G., Morley, T., Chan,  
583 S., Blows, F., Coulson, D. and Reuter, G., 2007. The DrosDel deletion collection: a *Drosophila* genome-  
584 wide chromosomal deficiency resource. *Genetics*.
- 585 Sambrook, J., Fritsch, E.F. and Maniatis, T., 1989. *Molecular cloning: a laboratory manual* (No. Ed. 2).  
586 Cold spring harbor laboratory press.
- 587 Schmidt, M.J., West, S. and Norbury, C.J., 2011. The human cytoplasmic RNA terminal U-transferase  
588 ZCCHC11 targets histone mRNAs for degradation. *Rna*, 17(1), pp.39-44.
- 589 Thibault, S.T., Singer, M.A., Miyazaki, W.Y., Milash, B., Dompe, N.A., Singh, C.M., Buchholz, R.,  
590 Demsky, M., Fawcett, R., Francis-Lang, H.L. and Ryner, L., 2004. A complementary transposon tool kit  
591 for *Drosophila melanogaster* using P and piggyBac. *Nature genetics*, 36(3), p.283.
- 592 Thibault, S.T., Singer, M.A., Miyazaki, W.Y., Milash, B., Dompe, N.A., Singh, C.M., Buchholz, R.,  
593 Demsky, M., Fawcett, R., Francis-Lang, H.L. and Ryner, L., 2004. A complementary transposon tool kit  
594 for *Drosophila melanogaster* using P and piggyBac. *Nature genetics*, 36(3), p.283.
- 595 Truman, J.W. and Bate, M., 1988. Spatial and temporal patterns of neurogenesis in the central nervous  
596 system of *Drosophila melanogaster*. *Developmental biology*, 125(1), pp.145-157.
- 597 Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. and Kinzler, K.W., 2013.  
598 Cancer genome landscapes. *Science*, 339(6127), pp.1546-1558.
- 599 Woods, D.F. and Bryant, P.J., 1989. Molecular cloning of the lethal (1) discs large-1 oncogene of  
600 *Drosophila*. *Developmental biology*, 134(1), pp.222-235.
- 601 Xu, J. and Chua, N.H., 2012. Dehydration stress activates Arabidopsis MPK6 to signal DCP1  
602 phosphorylation. *The EMBO journal*, 31(8), pp.1975-1984.
- 603 Xu, J., Yang, J.Y., Niu, Q.W. and Chua, N.H., 2006. Arabidopsis DCP2, DCP1, and VARICOSE form a  
604 decapping complex required for postembryonic development. *The Plant Cell*, 18(12), pp.3386-3398.
- 605 Yunis, J.J., 1983. The chromosomal basis of human neoplasia. *Science*, 221(4607), pp.227-236.



1


2 **FIGURE 1** Homozygous *l(3)tb* show delayed larval development with lethality at larval/pupal stage (A,  
 3 B) and is not a conditional temperature sensitive allele (A, B, C). Homozygous *l(3)tb* progeny, at 23°C,  
 4 showed lethality at larval and pupal stages and no flies eclosed as compared to wild type and  
 5 heterozygous *l(3)tb* progeny with balancer chromosome (A). Homozygous *l(3)tb* progeny individuals  
 6 demonstrated extended larval life up to day 12/13 where as heterozygous progeny individuals followed  
 7 the normal wild type pattern of development (B). (C) and (D) show significant increase in viability of  
 8 homozygous (non-tubby) *l(3)tb* larvae at lowered temperatures of 18°C and 16°C respectively, though  
 9 there also occurred absolute lethality at pupal stages. Each bar represents mean (±S.E.) of three replicates  
 10 of 100 larvae in each. \*\*\* indicates p<0.005 \*\*\* indicates p<0.005.





11

12 **FIGURE 2** Homozygous *l(3)tb* mutants show severe morphological alteration in delayed 3<sup>rd</sup> instar larval  
 13 brain, wing and eye-antennal disc of. Homozygous *l(3)tb* mutant 3<sup>rd</sup> instar larvae revealed tumorous brain  
 14 of day 12 (C) as compared to day 6 of homozygous mutant (B) and day 5 of wild type, *Oregon R<sup>+</sup>* (A).  
 15 *l(3)tb* homozygotes exhibited highly significant differences in the overall circumference of the left and  
 16 right brain lobes in the delayed stage (day 10) as compared to the respective wild type brain lobes (J).  
 17 Significant differences were found in the area (µm<sup>2</sup>) of respective brain lobes of *l(3)tb* homozygotes and  
 18 wild type (K). Dimension of wing and eye-antennal imaginal discs of delayed 3<sup>rd</sup> instar larvae from  
 19 homozygous *l(3)tb* mutant revealed significant increase in size (D,E,F,G). Length and breadth of wing  
 20 discs from 3<sup>rd</sup> instar larvae of *l(3)tb* mutant of day 6, was found to be smaller than the wing imaginal discs  
 21 from wild type, but wing discs from extended larval period (day 10) showed significant increase in the  
 22 size (L). Metaphase chromosome preparation of brain cells (H) from wild type and *l(3)tb* homozygotes  
 23 exhibited abnormal karyotypes (I) where *l(3)tb* homozygotes showed less condensed and extended  
 24 chromosome morphology as compared to wild type, *Oregon R<sup>+</sup>*. \*\*\* denotes p<0.005



26


27 **FIGURE 3** Enhanced mitotic potential observed in the tumorous tissues of homozygous *l(3)tb* as shown  
 28 in larval whole brain (A), brain lobes (D, G) and wing imaginal discs (S) immunostained with phosphor-  
 29 histone 3 (PH3), a potent mitotic marker. Distribution of PH3 labeled cells counter stained with DAPI  
 30 cells in wild type (A) and homozygous *l(3)tb* (Day 6 and Day 10) larval brain (D, G) and also in wild type  
 31 brain lobes (B, C) and homozygous mutant brain lobes (E, F for day 6; H, I for day 10) indicated high  
 32 mitotic index as compared to wild type. Similarly, more mitotic positive cells were seen in tumorous wing  
 33 imaginal discs (day 10) of homozygous mutant *l(3)tb* (II-D,E) as compared to wild type, *Oregon R+* (A  
 34 and B). DIC images (C,F,I and C,F) illustrates external normal morphology in wild type and more  
 35 pronounced tumorous phenotypes in homozygous *l(3)tb* larval brain and wing imaginal discs.

36 Quantitative analysis showed increase in the number of mitotic positive cells in homozygous mutant  
37 larval brain lobes and wing imaginal discs as compared to wild type and difference was highly significant  
38 (IV). The images are projections of optical sections taken by confocal microscope, Scale bar 100 $\mu$ m (I, II)  
39 and 50  $\mu$ m (III), Staining was done in triplicates with 10 brains and 15 wing imaginal discs in each group.  
40 Significant difference is represented as \*\*\*  $P \leq 0.005$  using one-way ANOVA.

41

42

43




44

45 **FIGURE 4** Confocal photomicrograph of 3<sup>rd</sup> instar larval brain showing the distribution pattern of DE-  
46 cadherin (Green) and Fasciclin II (red). Strong expression of DE-Cad throughout the brain lobes seen in  
47 homozygous *l(3)tb* (D) whereas wild type shows specific regions (A). Fas II expression is also altered in  
48 homozygous *l(3)tb* (E) as compared to wild type (B). Scale bar 100 μm.

49




50



51

52 **FIGURE 5** Confocal images of 3<sup>rd</sup> instar larval wing imaginal discs immunolabeled to visualize the  
53 altered distribution pattern of cadherin-catenin complex proteins. Tumor caused in the homozygous *l(3)tb*  
54 mutant completely altered the distribution pattern of both, trans-membranous protein DE-cadherin (A, E,  
55 I, M, Q) and Armadillo ( $\beta$ -Catenin, B, F, J, N, R) adheren junctional proteins. Alteration of both proteins  
56 is more pronounced in the wing imaginal discs from mutant larva during extended larval life (I, J) than in  
57 the early wing imaginal disc (E, F) as compared to distinct pattern of DE-cadherin (A) and Armadillo (B)  
58 in the wild type wing imaginal discs. Armadillo is a binding partner of trans-membranous protein DE-  
59 cadherin having roles in cell adhesion and regulate tissue organization and morphogenesis. Merged  
60 images also substantiate the altered distribution of both junctional proteins in the homozygous mutant (H,  
61 L) as compared to the wild type (D) where co-localization is indicated by yellow pattern. Higher  
62 magnification of wing imaginal disc (pouch region) demonstrate altered distribution pattern of DE-  
63 cadherin (Q) and Armadillo (R) in homozygous *l(3)tb* mutant as compared to wild type (N, R). Increase  
64 in cell size seen in homozygous *l(3)tb* mutant (Q) as compared to wild type (M). Complete loss of Arm

65 staining observed in homozygous *l(3)tb*(R) whereas normal pattern seen in wild type wing disc (N).  
66 Chromatin size also altered in homozygous *l(3)tb* (S) as compared to wild type (O). Wild type shows  
67 clear co-localization of D-Cad and Arm (P), while there is complete loss of co-localization in  
68 homozygous *l(3)tb* wing imaginal discs (T). Scale bar represents 100  $\mu\text{m}$  (A to L) and 10  $\mu\text{m}$  (M to T).




70 **FIGURE 6** Confocal photomicrograph show loss of mature neurons and increase in junctional protein,  
71 Dlg, in delayed (Day 10) homozygous *l(3)tb*. 3<sup>rd</sup> instar larval brain shows intense staining of Elav (green)  
72 in day 6 (D) of homozygous mutant later on show loss of staining in enlarged brain of day 10 (G), while  
73 the wild type brain (A) showed normal pattern of Elav staining. Dlg stained the ventral nerve chord and  
74 central brain in optic lobes of wild type (B), which is similar in day 6 of homozygous mutant brain (E) but  
75 in delayed larval brain, day 10, the pattern was altered (H). Scale shown is 100µm. Neuronal tissue from  
76 eye imaginal discs also display loss of neurons seen through Elav staining in day 10 (R) as compared to  
77 day 6 (N) in homozygous *l(3)tb* mutant as well as to wild type (J). Pattern of junctional protein, Dlg, in  
78 eye imaginal discs is also altered in day 10 (S) as compared to day 6 (O) and wild type (K). Counter stain  
79 with DAPI shows very weak intensity in day 10 (T) reflecting disintegrating chromatin as compared to  
80 day 6 (P) and wild type (L). Scale bar represents 10µm. Western blot for comparison of Dlg protein in  
81 wild-type (+/+), day 6 and day 10 *l(3)tb* mutant larval brain showed increased Dlg protein in homozygous  
82 mutant larval brain (V). β-tubulin has been used as an internal control.

83





84



85

86 **FIGURE 7** Viability assay performed on various hetero-allelic combinations between alleles of gene  
 87 *DCP2* and the mutation in *l(3)tb*. Homozygous *l(3)tb* exhibited larval as well as pupal lethality. 69% of  
 88 homozygous larvae pupated whereas no fly eclosed from the pupae. *l(3)tb* trans-heterozygous with  
 89  $P\{GT1\}DCP2^{BG01766}$  showed only 18.4% fly eclosed (A).  $l(3)tb/PBac\{RB\}DCP2^{e00034}$  trans-heterozygote  
 90 (C) causes 100% lethality at pupal stage. Trans-allelic combination  $P\{GT1\}DCP2^{BG01766}/$   
 91  $PBac\{RB\}DCP2^{e00034}$  (E) also exhibited 100% pupal lethality. Developmental delay seen in trans-  
 92 heterozygotes  $l(3)tb/P\{GT1\}DCP2^{BG01766}$  (B) and  $l(3)tb/PBac\{RB\}DCP2^{e00034}$  (D) as in homozygous  
 93 *l(3)tb*. Progeny from heterozygous for both the alleles of *DCP2* gene,  $PBac\{RB\}DCP2^{e00034}/$   
 94  $P\{GT1\}DCP2^{BG01766}$  (F) also exhibited developmental delay. \*\*\* indicates  $p < 0.005$ .

95




96

97 **FIGURE 8** Heterozygous combination of *l(3)tb* with *Dcp2<sup>e00034</sup>* allele resulted in to significant increase  
 98 in the number of neuroblasts and mitotically active cells. Confocal projection sections showing  
 99 immunolocalisation of Deadpan, a neuroblast marker (Green, A, F, K) for picking neuroblasts and  
 100 phosphohistone 3 (PH3, red, B, G, L) marking the mitotic cells are shown. Enhanced neuroblast  
 101 population in homozygous mutant (F) and in heterozygous *l(3)tb* with *Dcp2<sup>e00034</sup>* allele (K) Similarly,  
 102 increased number of mitotic cells (PH3 positive) also occurred in heterozygous *l(3)tb* with *Dcp2<sup>e00034</sup>*  
 103 allele (L), similar to homozygous *l(3)tb* mutant (G). NBs and mitotic positive cells are quantified (P) and

104 the differences are statistically significant when compared with wild type. \*\*\*  $P > 0.005$ . Scale bar  
105 indicates 50 $\mu$ m.

106



107

108 **FIGURE 9** Mutations found in the 5' UTR and promoter of *DCP2* in genomic DNA of *l(3)tb*  
 109 homozygotes. Chromatograms show single nucleotide changes at positions **3L:15819202(A>G)**;  
 110 **3L:15819384(A>G)**; **3L:15819446(A>C)** on plus strand (A-D). Three mutations lie in the 5'UTR of  
 111 *DCP2* and one transversion **3L:15819691(T>G)** lie in the promoter of *DCP2*. All nucleotides are  
 112 numbered according to FB2013\_05 *Dmel* Release 5.53 (FlyBase). A schematic representation of *DCP2*  
 113 depicting the insertion of the P-elements in the two insertion alleles, viz., *DCP2*<sup>e00034</sup> and *DCP2*<sup>BG01766</sup> is  
 114 shown in E. Note the nucleotide change in the promoter in the *l(3)tb* mutant. Analysis of *DCP2*  
 115 expression shows absence of *DCP2* transcripts in homozygous *l(3)tb* mutant (F). Note that the primer pair  
 116 generates different sized amplicons for genomic and cDNA. Although the genomic region coding for the  
 117 transcript is present in the mutant genome, it fails to code for the same.

118

119 **TABLE 1 Homozygous mutation in *l(3)tb* causes larval and pupal lethality.**

<b>Genetic cross (23<sup>0</sup>C<sub>±</sub>1)</b>	<b>Total Eggs</b>	<b>No. of eggs hatched</b>	<b>3<sup>rd</sup> Instar larva e transferred</b>	<b>Pupae formed</b>	<b>Flies eclosed</b>
			Non-Tubby- 468 (O=48.1%) (E= 50%)	Non-tubby 313 (O=66.8%)	Non Tubby 0
<b><i>l(3)tb/TM6B</i> X</b>	1500	972 (O= 64.8%) (E=66.7%)	Tubby 473 (O= 48.6%) (E=50%)	Tubby 468 (O=98.9%) (E=100%)	Tubby 465 (O=99.4%) (E=100%)

120 Numbers in parenthesis indicate the percentage observed (O) and expected (E) values out of the total  
121 progeny from previous stage.

122

123 **TABLE 2** Rearranged genotypes of 113 males after various recombination events between all the  
 124 eight visible markers of *rucuca* chromosome

S.No.	Genotypes								No. of Flies	Status of <i>l(3)tb</i> locus
1.	<i>ru</i>	<i>h</i>	<i>th</i>	+	+	+	+	+	1	1 <i>l</i> <sup>+</sup>
2.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	+	+	+	+	1	1 <i>l</i> <sup>+</sup>
3.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	+	+	+	1	1 <i>l</i> <sup>+</sup>
4.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	+	+	1	1 <i>l</i> <sup>+</sup>
5.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	+	3	3 <i>l</i> <sup>+</sup>
6.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	6	6 <i>l</i> <sup>+</sup>
7.	+	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	6	6 <i>l</i> <sup>+</sup>
8.	+	+	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	6	6 <i>l</i> <sup>+</sup>
9.	+	+	+	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	1	1 <i>l</i>
10.	+	+	+	+	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	2	1 <i>l</i>   1 <i>l</i> <sup>+</sup>
11.	+	+	+	+	+	<i>sr</i>	<i>e</i>	<i>ca</i>	2	2 <i>l</i>
12.	+	+	+	+	+	+	<i>e</i>	<i>ca</i>	4	4 <i>l</i>
13.	+	+	+	+	+	+	+	<i>ca</i>	6	6 <i>l</i>
14.	+	+	+	+	+	+	+	+	26	26 <i>l</i>
15.	<i>ru</i>	<i>h</i>	+	+	+	+	+	+	6	6 <i>l</i>
16.	<i>ru</i>	+	+	+	+	+	+	+	6	6 <i>l</i>
17.	<i>ru</i>	+	+	+	+	+	+	<i>ca</i>	3	3 <i>l</i>
18.	<i>ru</i>	+	+	+	+	+	<i>e</i>	<i>ca</i>	1	1 <i>l</i>
19.	<i>ru</i>	<i>h</i>	+	+	+	+	+	<i>ca</i>	7	7 <i>l</i>
20.	<i>ru</i>	<i>h</i>	+	+	+	<i>sr</i>	<i>e</i>	<i>ca</i>	5	5 <i>l</i>
21.	<i>ru</i>	+	+	+	+	<i>sr</i>	<i>e</i>	<i>ca</i>	3	3 <i>l</i>
22.	<i>ru</i>	<i>h</i>	+	+	<i>cu</i>	<i>sr</i>	<i>e</i>	<i>ca</i>	1	1 <i>l</i>
23.	<i>ru</i>	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	+	<i>e</i>	<i>ca</i>	1	1 <i>l</i> <sup>+</sup>
24.	+	+	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	+	<i>ca</i>	1	1 <i>l</i> <sup>+</sup>
25.	+	+	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	+	3	3 <i>l</i> <sup>+</sup>
26.	+	+	<i>th</i>	<i>st</i>	+	+	+	+	1	1 <i>l</i> <sup>+</sup>
27.	+	+	+	+	+	<i>sr</i>	<i>e</i>	+	1	1 <i>l</i> <sup>+</sup>
28.	+	<i>h</i>	+	+	+	+	+	+	1	1 <i>l</i> <sup>+</sup>
29.	+	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	<i>e</i>	+	5	4 <i>l</i> <sup>+</sup>   1 <i>l</i>
30.	+	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	<i>sr</i>	+	+	1	1 <i>l</i> <sup>+</sup>
31.	+	<i>h</i>	<i>th</i>	<i>st</i>	<i>cu</i>	+	+	+	1	1 <i>l</i> <sup>+</sup>
<b>Total</b>									<b>113</b>	

125

126

127 **TABLE 3 Recombination frequencies (RF) between various recessive markers on *rucuca***  
 128 **chromosomes (*roughoid*, *hairy*, *thread*, *scarlet*, *curled*, *stripe*, *ebony*, and *claret*) and *l(3)tb***

Sl. No.	Association of marker with <i>l(3)tb</i>	Flies				Recombination frequency (RF) $\frac{R}{P+R} \times 100$
		Parental (P)		Recombinant (R)		
		Genotype	No. of flies	Genotype	No. of flies	
1.	<i>ru - l</i>	<i>ru</i> <sup>+</sup> <i>l</i> <i>ru</i> <i>l</i> <sup>+</sup>	18 } 62 44	<i>ru</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>ru</i> <i>l</i>	18 } 51 33	45.13
2.	<i>h - l</i>	<i>h</i> <sup>+</sup> <i>l</i> <i>h</i> <i>l</i> <sup>+</sup>	54 } 79 25	<i>h</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>h</i> <i>l</i>	12 } 34 22	30.08
3.	<i>th - l</i>	<i>th</i> <sup>+</sup> <i>l</i> <i>th</i> <i>l</i> <sup>+</sup>	74 } 110 36	<i>th</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>th</i> <i>l</i>	1 } 3 2	2.65
4.	<i>st - l</i>	<i>st</i> <sup>+</sup> <i>l</i> <i>st</i> <i>l</i> <sup>+</sup>	73 } 108 35	<i>st</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>st</i> <i>l</i>	2 } 5 3	4.42
5.	<i>cu - l</i>	<i>cu</i> <sup>+</sup> <i>l</i> <i>cu</i> <i>l</i> <sup>+</sup>	71 } 105 34	<i>cu</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>cu</i> <i>l</i>	3 } 8 5	7.07
6.	<i>sr - l</i>	<i>sr</i> <sup>+</sup> <i>l</i> <i>sr</i> <i>l</i> <sup>+</sup>	62 } 94 32	<i>sr</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>sr</i> <i>l</i>	4 } 19 15	16.8
7.	<i>e - l</i>	<i>e</i> <sup>+</sup> <i>l</i> <i>e</i> <i>l</i> <sup>+</sup>	56 } 86 30	<i>e</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>e</i> <i>l</i>	7 } 27 20	23.89
8.	<i>ca - l</i>	<i>ca</i> <sup>+</sup> <i>l</i> <i>ca</i> <i>l</i> <sup>+</sup>	42 } 74 32	<i>ca</i> <sup>+</sup> <i>l</i> <sup>+</sup> <i>ca</i> <i>l</i>	16 } 49 33	43.3

130

131 **TABLE 4** Recombination events between *h-l*, *st-l* and *cu-l*

S.No.	Association of marker with <i>l(3)tb</i>	Flies				Recombination frequency $\frac{R}{P+R} \times 100$		
		Parentals (P)		Recombinants (R)				
		Genotype	No. of flies	Genotype	No. of flies			
1.	<i>h - l</i>	<i>h<sup>+</sup> l</i>	89	} 185	<i>h<sup>+</sup> l<sup>+</sup></i>	18	} 40	17.78
		<i>h l<sup>+</sup></i>	96		<i>h l</i>	22		
2.	<i>st - l</i>	<i>st<sup>+</sup> l</i>	252	} 480	<i>th<sup>+</sup> l<sup>+</sup></i>	2	} 6	1.23
		<i>st l<sup>+</sup></i>	238		<i>th l</i>	4		
3.	<i>cu - l</i>	<i>cu<sup>+</sup> l</i>	269	} 552	<i>ru<sup>+</sup> l<sup>+</sup></i>	22	} 50	8.29
		<i>cu l<sup>+</sup></i>	283		<i>ru l</i>	28		

132

133



134 **TABLE 5 Fertility assay of trans-heterozygotes  $P\{GT1\}DCP2^{BG01766}/l(3)tb$  demonstrating male and**  
135 **female sterility**


	$l(3)tb/P\{GT1\}DCP2^{BG01766}$ (males)	$l(3)tb/P\{GT1\}DCP2^{BG01766}$ (Virgin females)
<b>Cross</b>	X +/+ (Virgin females)	X +/+ (males)
<b>Total No. of Pair Mating</b>	70	83
<b>Fertile</b>	28 (40%)	18 (21.7%)
<b>Sterile</b>	42 (60%)	55 (66.3%)

136


137

138 **Table 6 Global overexpression of *DCP2* rescues the mutant phenotypes exhibited by *l(3)tb***


Genetic Crosses		<i>Act5C-GAL4/CyO</i> ; +/+		+/+; <i>Tub-GAL4/TM6B</i>		<i>Act5C-GAL4/CyO</i> ; <i>l(3)tb/TM6B</i>		<i>UAS-DCP2/CyO</i> ; <i>l(3)tb/TM6B</i>	
		X		X		X		X	
		<i>Act5C GAL4/CyO</i> ; +/+		+/+; <i>Tub GAL4/TM6B</i>		<i>Sp/CyO</i> ; <i>l(3)tb</i> : <i>UAS-DCP2/TM6B</i>		<i>Sp/CyO</i> ; <i>l(3)tb</i> : <i>Tub GAL4/TM6B</i>	
		Homozygotes die as embryos or early larvae		Homozygotes die as embryos or early larvae		CyO and TM6B homozygotes die as embryos or early larvae		CyO and TM6B homozygotes die as embryos or early larvae	
01.	Eggs	<b>750</b>		<b>790</b>		<b>1050</b>		<b>1245</b>	
02.	Unfertilised Eggs	39	5.2%	37	4.7%	68	6.5%	86	6.9%
03.	Fertilised Eggs	711	94.8%	753	95.3%	982	93.5%	1159	93.1%
04.	Dead Embryos	304	42.8%	357	47.4%	434	44.2%	525	45.3%
05.	Dead 1 <sup>st</sup> and 2 <sup>nd</sup> instar Larvae	8	1.12%	19	2.52%	34	3.46%	57	4.92%
06.	Dead 3 <sup>rd</sup> instar larvae	2	0.28%	5	0.66%	72	7.33%	128	11.04%
07.	Pupae	<b>397</b>	55.8%	<b>372</b>	49.4%	<b>442</b>	45.0%	<b>449</b>	38.7%
08.	Dead Pupae	17	4.3%	11	2.9%	21	4.8%	23	5.1%
09.	Eclosion following over-expression of <i>DCP2</i> in homozygous <i>l(3)tb</i> background	-	-	-	-	<i>Act5C-GAL4/CyO</i> ; <i>l(3)tb</i> : <i>UAS-DCP2/l(3)tb</i>		<i>UAS-DCP2/CyO</i> ; <i>l(3)tb</i> : <i>Tub-GAL4/l(3)tb</i>	
						94	<b>21.3%</b>	77	<b>17.2%</b>
		-	-	-	-	<i>Act5C-GAL4/Sp</i> ; <i>l(3)tb</i> : <i>UAS-DCP2/l(3)tb</i>		<i>UAS-DCP2/Sp</i> ; <i>l(3)tb</i> : <i>Tub-GAL4/l(3)tb</i>	
						61	<b>13.8%</b>	89	<b>19.8%</b>




**FIGURE S1** Reversion analysis by the excision of *piggyBac* transposon in  $DCP2^{00034}$  with the help of *piggyBac* specific transposase source, *CyO*,  $P\{Tub-Pbac\}2/Wg^{SP-1}$  and similarly by the excision of *P*-element in  $DCP2^{BG01766}$  strain using  $\Delta 2-3, Sb/TM6B$ ,  $Tb^1$ , *Hu*,  $e^1$  transposase source as ‘jumpstarter stock’. *DCP2* revertant white eyed F2 flies were crossed to *l(3)tb* and lethal progenies scored.




**FIGURE S2.** Confocal images of 3<sup>rd</sup> instar larval brain lobe to visualize neurons through Elav (neuronal marker, green) co-labelled with septate junction marker Discs large, Dlg, (red). Confocal images of 3<sup>rd</sup> instar larval brain to show neurons through Elav (green) and co-labelled with Dlg (red) at higher magnification. This also showed intense staining of Elav in day 6 (D) of homozygous mutant larval brain lobe which showed loss of staining in enlarged brain lobe of day 10 (G), while the wild type brain lobe (A) showed normal pattern of Elav staining. Dlg stained both lial and neuronal cells and showed distinct pattern in optic lobes of wild type larval brain (B), which is similar in day 6 of homozygous mutant brain (E) but in delayed enlarged larval brain lobe, day 10, the pattern was altered (H). Scale shown is 50μm.




**FIGURE S3** Magnified image of notum region in 3<sup>rd</sup> instar larval wing imaginal discs immunolabeled to visualize the distribution pattern of DE-cadherin and  $\square\square$ Catenin. Distinct pattern of DE-cadherin (A) and Armadillo (B) immunostaining is visible in the wild type wing imaginal discs (notum region), which is absent in *l(3)tb* mutant wing imaginal disc (E & F respectively). The tissues were counterstained with DAPI (white). Scale bar is indicative of 50 µm.



**FIGURE S4** Magnified image of pouch region in 3<sup>rd</sup> instar larval wing imaginal discs immunolabeled to visualize the distribution pattern of D-cadherin and  $\square\square$ Catenin. Cadherin staining was done with anti-DCadherin antibody (green) and  $\square$ -Catenin staining was done with anti-Armadillo antibody (red) followed by counterstaining with DAPI (white). Scale bar indicates 50  $\mu$ m.




**FIGURE S5. Confocal images of 3<sup>rd</sup> instar larval leg imaginal discs immunolabeled to visualize the distribution pattern of DE-cadherin-catenin (green) complex proteins. Armadillo (□-Catenin, red) is a binding partner of trans-membranous protein DE-cadherin (green) having roles in cell adhesion and regulate tissue organization and morphogenesis. Scale bar indicates 50  $\mu$ m**




**FIGURE S6** Confocal image of 3<sup>rd</sup> instar larval brain lobes extending the distribution pattern of DE-cadherin (Green) and Fasciclin II (red). The pattern shown by DE cadherin, which labels the surface glia and neuropile glia, is altogether altered in the homozygous *l(3)tb* mutant (D) as compared to wild type (A) which shows strong staining in neuropile glia. Fas II labels the pioneering axonal fascicles in wild type (B) as shown by the marked mushroom body, MB, which is absent in the homozygous *l(3)tb* mutant (E). Fas II Images in C and E demonstrate the merged images of wild type and mutant respectively. Scale bar is 50 μm.







**FIGURE S7** Tumorous larval brain phenotype in trans-heterozygous *l(3)tb* with *Df(3L)BSC575*. The deletion line, *Df(3L)BSC575*, do not show complementation with *l(3)tb* and the larvae showed tumorous brain in trans-heterozygous condition (B, C) when compared to wild type (A).




**FIGURE S8.** Morphological defects exhibited by escapees of adult fly trans-heterozygous for  $P\{GT1\}DCP2^{BG01766}/l(3)tb$ . The phenotype includes melanotic patches (22.2%) on the cuticular exoskeleton, abnormalities in leg (41.3%), wing (10%), abdomen (3.2%) and thorax (3.2%). Many of the trans-heterozygous progeny was observed to have eclosion problem (12.7%) and males have abnormal genitalia (9.7%).



**FIGURE S9. Pronouncement of severe defects in compound eyes of the escapees having heterozygous genetic background of the mutant *l(3)tb* with lethal *P*-insertion allele *DCP2*<sup>BG01766</sup>.** Images in A and B showing the compound eye of wild type and trans-heterozygote respectively while A' and B' are their respective nail-polish imprint of the compound eye, viewed with the help of DIC or Nomarski microscope. The exact geometrical arrangement of ommatidia in a hexagonal pattern having each ommatidium surrounded by bristle was completely disrupted in the trans-heterozygote exhibiting the complete loss of arrangement in the ommatidial pattern. This represents the severe loss of polarity as it cues a complete disassembly of compound eye as whole. Bar represents 20 $\mu$ m.



**FIGURE S10.** Tumorous phenotype observed in larval brain and wing imaginal discs in trans-heterozygotes  $l(3)tb /PBac\{RB\}Dcp2^{e00034}$  and  $l(3)tb /P\{GT1\}Dcp2^{BG01766}$  as homozygous  $l(3)tb$ . Scale bar is 100 $\mu$ m.



**FIGURE 11** Amplification of DCP2 gene using overlapping primers. All primers amplify same size of amplicon with DNA from wild type and homozygous *l(3)tb* mutant, except DCP2\_P19 (3L:15819379..15819751) and DCP2\_P19\_2 (3L:15819452..15819569). This implies the probable mutation in the region.

**TABLE S1.** Various deletion lines used for complementation with the mutation in *l(3)tb*. All the below deletion lines complemented with the mutation in *l(3)tb* except *Df(3L)BSC845*, *Df(3L)BSC774* and *Df(3L)BSC575* which resulted in non-complementation to the mutation in *l(3)tb*. [\* = marked *Df(3L)RM95*, molecularly characterized deletion generated in the laboratory and also exhibiting non-complementation].

S. No.	Deletion Lines	Estimated Cytology	Genomic Sequence Co-ordinates of Break points (Proximal; Distal)	Deleted Region (in base)	Status of Complementation
1.	<i>Df(3L)ED4079</i>	61A5;61B1	3L:40319; 131780	715336	Yes
2.	<i>Df(3L)ED201</i>	61B1;61C1	3L:123924; 347941	347941	Yes
3.	<i>Df(3L)ED4177</i>	61C1;61E2	3L:319846; 1035182	1035182	Yes
4.	<i>Df(3L)ED4287</i>	62B4;62E5	3L:1795442; 2551761	756319	Yes
5.	<i>Df(3L)ED4288</i>	63A6;63B7	3L:3070827; 3149091	78264	Yes
6.	<i>Df(3L)ED208</i>	63C1;63F5	3L:3249148; 3893148	644000	Yes
7.	<i>Df(3L)ED4341</i>	63F6;64B9	3L:3905091; 4542236	637145	Yes
8.	<i>Df(3L)ED210</i>	64B9;64C13	3L:4544234; 5348442	804208	Yes
9.	<i>Df(3L)ED211</i>	65A9;65B4	3L:6211235; 6545859	334624	Yes
10.	<i>Df(3L)ED4408</i>	66A22;66C5	3L:7972207; 8292674	320467	Yes
11.	<i>Df(3L)ED4421</i>	66D12;67B3	3L:8738426; 9377175	638749	Yes
12.	<i>Df(3L)ED4457</i>	67E2;68A7	3L:10357051; 11118909	761858	Yes
13.	<i>Df(3L)ED4470</i>	68A6;68E1	3L:11090089; 11826330	736241	Yes
14.	<i>Df(3L)ED4475</i>	68C13;69B4	3L:11580140; 12401701	821561	Yes
15.	<i>Df(3L)ED4483</i>	69A5;69D3	3L:12270320; 12686314	415994	Yes
16.	<i>Df(3L)ED4486</i>	69C4;69F6	3L:12507519; 13025585	518066	Yes
17.	<i>Df(3L)ED4502</i>	70A3;70C10	3L:13220865; 13986651	765786	Yes
18.	<i>Df(3L)ED4543</i>	70C6;70F4	3L:13928325; 14751140	822815	Yes
19.	<i>Df(3L)ED217</i>	70F4;71E1	3L:14751170; 15582196	831026	Yes
20.	<i>Df(3L)BSC833</i>	71D4;71F1	3L:15507245; 15671057	163812	Yes
21.	<i>Df(3L)RM95*</i>	71E1;72B2	3L:15481449; 15904040	422591	NO
22.	<i>Df(3L)BSC845</i>	71D3;72A1	3L:15504128; 15819023	314895	NO
23.	<i>Df(3L)BSC575</i>	71F1;72C1	3L:15671057; 15973064	302007	NO
24.	<i>Df(3L)BSC774</i>	71F1;72D10	3L:15693003; 16233380	540377	NO
25.	<i>Df(3L)Exel6127</i>	72D1;72D9	3L:16040040; 16122754	82714	Yes
26.	<i>Df(3L)ED223</i>	73A1;73D5	3L:16444925; 16883977	439052	Yes
27.	<i>Df(3L)ED4674</i>	73B5;73E5	3L:16654384; 17042518	388134	Yes
28.	<i>Df(3L)ED4685</i>	73D5;74E2	3L:16884176; 17605270	721094	Yes
29.	<i>Df(3L)ED4710</i>	74D1;75B11	3L:17480563; 18132399	651836	Yes
30.	<i>Df(3L)ED224</i>	75B1;75C6	3L:17962303; 18391619	429316	Yes
31.	<i>Df(3L)ED225</i>	75C1;75D4	3L:18179245; 18614437	435192	Yes

32.	<i>Df(3L)ED4782</i>	75F2;76A1	3L:18988994; 19163802	174808	Yes
33.	<i>Df(3L)ED4786</i>	75F7;76A5	3L:19094051; 19288762	194711	Yes
34.	<i>Df(3L)ED229</i>	76A1;76E1	3L:19163806; 19995811	832005	Yes
35.	<i>Df(3L)ED4858</i>	76D3;77C1	3L:19888473; 20394920	506447	Yes
36.	<i>Df(3L)ED4978</i>	78D5;79A2	3L:21526907; 21873785	346878	Yes
37.	<i>Df(3L)ED230</i>	79C2;80A4	3L:22127751; 22827471	699720	Yes
38.	<i>Df(3L)ED5017</i>	80A4;80C2	3L:22828597; 22991401	162804	Yes
39.	<i>Df(3R)ED5100</i>	82A1;82E8	3R:22995; 912807	889812	Yes
40.	<i>Df(3R)ED5138</i>	82D5;82F8	3R:606794; 1090605	483811	Yes
41.	<i>Df(3R)ED5142</i>	82B3;82F8	3R:279018; 1090605	811587	Yes
42.	<i>Df(3R)ED5147</i>	82E8;83A1	3R:912842; 1193526	280684	Yes
43.	<i>Df(3R)ED5156</i>	82F8;83A4	3R:1090655; 1284574	193919	Yes
44.	<i>Df(3R)ED10257</i>	83A7;83B4	3R:1344078; 1426000	81922	Yes
45.	<i>Df(3R)ED5177</i>	83B4;83B6	3R:1426351; 1449817	23466	Yes
46.	<i>Df(3R)ED5197</i>	83B7;83D2	3R:1474504; 1833866	359362	Yes
47.	<i>Df(3R)ED7665</i>	84B4;84E11	3R:2916249; 3919805	1003556	Yes
48.	<i>Df(3R)ED5230</i>	84E6;85A5	3R:3803496; 4478856	675360	Yes
49.	<i>Df(3R)ED5296</i>	84F6;85C3	3R:4076143; 4882413	806270	Yes
50.	<i>Df(3L)ED5330</i>	85A5;85D1	3R:4495308; 5055517	560209	Yes
51.	<i>Df(3R)ED5339</i>	85D1;85D11	3R:5052798; 5178097	125299	Yes
52.	<i>Df(3R)ED5429</i>	85D21;85F8	3R:5336031; 5874333	538302	Yes
53.	<i>Df(3L)ED5454</i>	85E5;85F12	3R:5552399; 5937180	384781	Yes
54.	<i>Df(3R)ED5474</i>	85F11;86B1	3R:5935134; 6176446	241312	Yes
55.	<i>Df(3L)ED5495</i>	85F16;86C7	3R:5996223; 6712482	716259	Yes
56.	<i>Df(3R)ED5559</i>	86E11;87B11	3R:7394904; 8269738	874834	Yes
57.	<i>Df(3L)ED5577</i>	86F9;87B13	3R:7654463; 8303300	648837	Yes
58.	<i>Df(3L)ED5591</i>	87B7;87C7	3R:8176253; 8545732	369479	Yes
59.	<i>Df(3R)ED5610</i>	87B11;87D7	3R:8269738; 8821397	551659	Yes
60.	<i>Df(3L)ED5623</i>	87E3;88A4	3R:9085471; 9809634	724163	Yes
61.	<i>Df(3R)ED5642</i>	87F10;88C2	3R:9509544; 10307496	797952	Yes
62.	<i>Df(3R)ED5644</i>	88A4;88C9	3R:9843625; 10451431	607806	Yes
63.	<i>Df(3R)ED10639</i>	89B7;89D2	3R:12038635; 12306942	268307	Yes
64.	<i>Df(3R)ED10635</i>	89B13;89D2	3R:12174977; 12306942	131965	Yes
65.	<i>Df(3R)ED10642</i>	89C7;89D5	3R:12279479; 12450993	171514	Yes
66.	<i>Df(3L)ED5780</i>	89E11;90C1	3R:12882199; 13507523	625324	Yes
67.	<i>Df(3R)ED5785</i>	90C2;90D1	3R:13543832; 13769792	225960	Yes
68.	<i>Df(3L)ED5797</i>	90C2;90F10	3R:13543832; 14068391	524560	Yes
69.	<i>Df(3R)ED5815</i>	90F4;91B8	3R:13993596; 14484708	491112	Yes
70.	<i>Df(3R)ED2</i>	91A5;91F1	3R:14224953; 14922493	697540	Yes
71.	<i>Df(3R)ED5911</i>	91C5;91F8	3R:14568649; 14991505	422856	Yes
72.	<i>Df(3R)ED6025</i>	92A11;92E2	3R:15468450; 16135241	666791	Yes
73.	<i>Df(3R)ED10820</i>	93A4;93B12	3R:16774462; 16937182	162720	Yes
74.	<i>Df(3R)ED10845</i>	93B9;93D4	3R:16890893; 17122221	231328	Yes
75.	<i>Df(3R)ED6052</i>	93D4;93D8	3R:17122205; 17191074	68869	Yes
76.	<i>Df(3R)ED6076</i>	93E10;94A1	3R:17459227; 17868550	409323	Yes
77.	<i>Df(3L)ED6085</i>	93F14;94B5	3R:17706717; 18413461	706744	Yes
78.	<i>Df(3R)ED6096</i>	94B5;94E7	3R:18413403; 19047691	634288	Yes

<b>79.</b>	<i>Df(3R)ED6103</i>	94D3;94E9	3R:18724275; 19084137	359862	Yes
<b>80.</b>	<i>Df(3R)ED6187</i>	95D10;96A7	3R:19877370; 20369665	492295	Yes
<b>81.</b>	<i>Df(3R)ED6220</i>	96A7;96C3	3R:20369520; 21009495	639975	Yes
<b>82.</b>	<i>Df(3R)ED6235</i>	97B9;97D12	3R:22360956; 22806229	445273	Yes
<b>83.</b>	<i>Df(3R)ED6255</i>	97D2;97F1	3R:22624758; 23107623	482865	Yes
<b>84.</b>	<i>Df(3R)ED6265</i>	97E2;98A7	3R:22937981; 23405492	467511	Yes
<b>85.</b>	<i>Df(3R)ED6310</i>	98F12;99B2	3R:24964617; 25337875	373258	Yes
<b>86.</b>	<i>Df(3R)ED6316</i>	99A5;99C1	3R:25081045; 25608389	527344	Yes



**TABLE S2 Complementation status of *l(3)tb* with cytologically mapped deletion lines**

<b>S.No.</b>	<b>Bloomington Stock Number</b>	<b>Deletion Lines</b>	<b>Estimated Cytological Break points</b>	<b>Status of Complementation</b>
1.	BL: 6554	<i>Df(3L)XG8</i>	71C3-D1;71F2-5	No
2.	BL:6548	<i>Df(3L)XG1</i>	71C3-D1;71F2-5	No
3.	BL:6603	<i>Df(3L)X-21.2</i>	71F1;72A2	No
4.	BL:6157	<i>Df(3L)D-5rv12,e<sup>1</sup></i>	70C2;72A1	No
5.	BL:6558	<i>Df(3L)XG15</i>	71A3;71F4	Yes
6.	BL:3641	<i>Df(3L)th<sup>102</sup>,h<sup>1</sup>,kni<sup>ri-1</sup>,e<sup>1</sup></i>	72A2;72D10	Yes

**TABLE S3 Complementation analysis of *l(3)tb* with lethal transposon insertion lines**

S. No.	Stock	Symbol	Gene Affected/ Estimated cytology*	Genomic Sequence Coordinates*	Complementation Status
1.	18573	<i>PBac{WH}DCX-EMAP<sup>02655</sup></i>	<i>DCX-EMP</i> 71A2	3L:14933115..14933115	YES
2.	12791	<i>P{GT1}mnd<sup>BG01434</sup></i>	<i>minidiscs (mnd)</i> 71A4	3L:14980561..14980561	YES
3.	17084	<i>P{EP}Prosbeta2<sup>EP306</sup></i> 7	<i>Proteosome <math>\beta</math>2</i> <i>subunit</i> 71B1	3L:14993119..14993119	YES
4.	12089	<i>P{lacW}cp309<sup>s2172</sup></i>	<i>cp309</i> 71B3	3L:15072574..15072574	YES
5.	21206	<i>P{EPgy2}cp309<sup>EY1637</sup></i> 6	<i>cp309</i> 71B3	3L:15072713..15072713	YES
6.	16007	<i>P{EPgy2}Aats-gly<sup>EY09021</sup></i>	<i>Glycyl tRNA synthetase</i> 71B4	3L:15088255..15088255	YES
7.	12090	<i>P{lacW}l(3)j2A2<sup>j2A2</sup></i>	<i>lethal(3)j2A2</i> 71B5	3L:15134670..15134670	YES
8.	34467	<i>Mi{MIC}Toll-6<sup>M102127</sup></i>	<i>Toll-6</i> 71C2	3L:15332734	YES
9.	16100	<i>PBac{5HPw[+]}CG7841<sup>A372</sup></i>	<i>CG7841</i> 71D3	3L:15500292..15500292	YES
10.	21095	<i>P{EPgy2}CrebA<sup>EY134</sup></i> 94	<i>CrebA</i> 71E1	3L:15529167..15529167	YES
11.	10183	<i>P{PZ}CrebA<sup>03576</sup></i>	<i>CrebA</i> 71E1	3L:15537388..15537388	YES
12.	12091	<i>P{lacW}l(3)s1754<sup>s175</sup></i> 4	<i>lethal(3)s1754</i> 71E1	3L:15556710..15556710	YES
13.	12092	<i>P{lacW}RhoGAP71E<sup>j6B9</sup></i>	<i>RhoGAP71E</i> 71E1	3L:15582004..15582004	YES
14.	15523	<i>P{EPgy2}mrn<sup>EY01615</sup></i>	<i>marionette</i> 71E1	3L:15573609..15573609	YES
15.	12100	<i>P{lacW}RhoGAP71E<sup>s1629a</sup></i>	<i>RhoGAP71E</i> 71E1	3L:15582004..15582004	YES
16.	17134	<i>P{EP}RhoGAP71E<sup>EP</sup></i> 3492	<i>RhoGAP71E</i> 71E1	3L:15586701..15586701	YES
17.	22649	<i>P{EPgy2}CG7650<sup>EY2</sup></i> 3633	<i>CG7650</i> 71E2	3L:15603462..15603462	YES
18.	23596	<i>Mi{ET1}CG7579<sup>MB02</sup></i> 986	<i>CG7579</i> 71F1	3L:15676129..15676129	YES
19.	16186	<i>PBac{5HPw<sup>+</sup>}B259</i>	71F2	3L:15700304..15700304	YES
20.	17644	<i>P{EPgy2}comm<sup>EY1015</sup></i> 4	<i>commisureless</i> 71F2	3L:15721560..15721560	YES
21.	21983	<i>P{EPg}fwe<sup>HP35545</sup></i>	<i>flower</i>	3L:15809466..15809466	

			72A1	09466	<b>YES</b>
<b>22.</b>	12794	<i>P{GT1}DCP2<sup>BG01766</sup></i>	<i>Decapping protein2</i> 72A1	3L:15819332..158 19332	<b>NO</b>
<b>23.</b>	23591	<i>Mi{ET1}CG32150<sup>MB</sup></i> <i>02846</i>	CG32150 72A2	3L:15834442..158 34442	<b>YES</b>
<b>24.</b>	25339	<i>Mi{ET1}pHCl<sup>MB06931</sup></i>	<i>pHCl</i> 72A3	3L:15863723..158 63723	<b>YES</b>
<b>25.</b>	22126	<i>P{EPg}HP36806</i>	72B2	3L:15948256..159 48256	<b>YES</b>

Allele of *Decapping protein 2* (*P{GT1}DCP2<sup>BG01766</sup>*), reported to be semi-lethal in the FlyBase showed non-complementation to the mutation in *l(3)tb*. \*Designates the current annotation and cytological positions and molecular insertion sites as per FlyBase (R5).

**TABLE S4 Primers used for characterizing deletion in *Df(3L)RM95*.**

PRIMER SYMBOL	PRIMER DETAILS						PARAMETER
	PRIMER (10 pmol/ $\mu$ L)	SEQUENCE (5'→3')	MOLECULAR POSITIONS (FlyBase, R5)	T <sub>m</sub> (°C)	'GC' (%)	AMPLICON SIZE (in bp)	T <sub>a</sub> (°C) / Ext. (sec)
Custom A	FOR	GCACCAACTGAGCTGTATC	15525318-	54.1	52.6	420	54 <sup>0</sup> C/ 30sec
PRY4	REV	CAATCATATCGCTGTCTCACTCA		60.3	43.5		
W7500D	FOR	GTCCGCCTTCAGTTGCACTT		62.7	55.0	1600	6 <sup>0</sup> C/ 1min
W11678U	REV	TCATCGCAGATCAGAAGCGG		64.9	55.0		
3. PRY4	FOR	CAATCATATCGCTGTCTCACTCA	-15948402	60.3	43.5	360	54 <sup>0</sup> C / 1min
Custom B	REV	TAGTCCACGTAAGGTGCAC		54.3	55.6		

Custom A and custom B primers were designed from the genomic region upstream and downstream to the region where the P{RS5} and P{RS3} progenitor element localized so that with the combination of PRY4, could give 420 bp and 360 bp amplicon respectively.

**TABLE S5** First set of primers used for amplification of genomic region of *Decapping protein 2* in the mutant *l(3)tb*.

PRIMER SYMBOL	PRIMER DETAILS						THERMAL CYCLER PARAMETER Ta (°C) / Ex. Time (sec)
	PRIMER (10 pmol/μL)	SEQUENCE (5'→3')	MOLECULAR POSITIONS (FlyBase, R5)	Tm (°C)	'GC' (%)	AMPLICON SIZE (in bp)	
1_DCP2	FOR	TCATTTCGAACGGTGTGTGT	15813468-15815531	60.0	45.0	2063	56 <sup>0</sup> C/ 2 min
	REV	TTGCAAGAAGGACGTCACAG		60.0	50.0		
2_DCP2	FOR	CGGCATAATCATGAAGAAGGA	15815651-15817968	60.0	42.9	2318	58 <sup>0</sup> C/ 2min 30s
	REV	AGTCTACGTTATCGGGGTCGT		59.9	52.4		
3_DCP2	FOR	TGATTTCGATAAGCACCCCTTG	15817566-15820015	60.1	42.9	2450	58 <sup>0</sup> C/ 3min
	REV	CGATTGGTATGGCGATAGAGA		60.1	47.6		

**TABLE S6** Overlapping set of primers for *DCP2* gene and thermal cycler conditions of annealing temperature and extension time for each primer pair to amplify the genomic region of *DCP2* gene in the homozygous *l(3)tb* mutant.

PRIMER SYMBOL	PRIMER DETAILS					
	PRIMER (10 pmol/μL)	SEQUENCE (5'→3')	MOLECULAR POSITIONS (FlyBase, R5)	T <sub>m</sub> (°C)	'GC' (%)	AMPLICON SIZE (in bp)
DCP2_P1	FOR	AGGCTTCTCTCCCCGTAAC	15813182-15813746	62.7	57.1	565
	REV	CTGCGGGGCGAGAACACGAT		70.0	65.0	
DCP2_P2	FOR	TTCATAGGTGGGGGCGGGCA	15813671-15814201	71.8	65.0	531
	REV	ACGTTAGGGAACCACAAACACACCT		65.9	48.0	
DCP2_P3	FOR	TGTGCTGAGCGGAAGACTCTCGTTT	15814054-15814635	69.5	52.0	582
	REV	GCAGCAGCTGGGAATCGACTTTACG		70.7	56.0	
DCP2_P4	FOR	ATTTGGCGTAAAGTCGATTC	15814605-15815184	56.9	40.0	580
	REV	CAAGCAATGAGAAGGTGAGT		55.4	45.0	
DCP2_P5	FOR	AGGATTTTGA CTGGCTGCTG	15814960-15815231	60.4	50.0	272
	REV	GCGTCAACTGTTCCATAGCC		60.7	55.0	
DCP2_P6	FOR	GGAACAGTTGACGCTTCGAG	15815218- 15815640	61.0	55.0	423
	REV	GCCTGAAGAAGTGGGTGAAC		59.7	55.0	
DCP2_P7	FOR	CTTATTGCGTTTCCCATTGC	15815330-15815709	60.5	45.0	380
	REV	ATGCCATATCAAAGGCCAAG		59.9	45.0	
DCP2_P8	FOR	AGCCTTCCGATCGTTCACCCAC	15815609-15815909	68.8	59.1	301
	REV	GGTTTATGAGGAGACCGGGTTCG		66.9	56.5	
DCP2_P9	FOR	ATGTTTCGCACCACGTACAG	15815802- 15816213	59.6	50.0	412
	REV	GCTATCGGTGCCCACTTATG		60.5	55.0	
DCP2_P10	FOR	ATAGCGCCATAAGTGGGCACCGATA	15816187-15816720	69.9	52.0	534
	REV	ACTCCTCCTACGGCAGCTCATCATC		68.0	56.0	
DCP2_P11	FOR	GATGATGAGCTGCCGTAGGAGGAGT	15816696-15817147	68.0	56.0	452
	REV	CTATCAGTTTCTTGGGGCCGTGTGC		70.4	56.0	
DCP2_P12	FOR	GCACACGGCCCCAAGAACTG	15817123-15817595	69.2	61.9	473
	REV	AGGCTCTTACAAAGGGTGCTTATCGA A		66.9	44.4	
DCP2_P13	FOR	TCGATAAGCACCCCTTGTAAAGAGCCT	15817570-15817972	66.2	46.2	403
	REV	CACCAGTCTACGTTATCGGGGTCGT		68.2	56.0	

DCP2_P14	FOR	AGTGCTGCAGTACGACCCCGATA	15817937-15818367	67.1	56.5	431
	REV	ACAATCAGAATATCTCCCACCCAGCA		67.7	46.2	
DCP2_P15	FOR	TGCTGGGTGGGAGATATTCTGATTGT	15818342-15818617	67.7	46.2	276
	REV	CGTCTCTGCCTCTGCTAGCGT		64.4	61.9	
DCP2_P16	FOR	ACGCTAGCAGAGGCAGAGAC	15818597- 15818806	59.9	60.0	210
	REV	CAGAGAGAGACGCGAATGTG		59.7	55.0	
DCP2_P17	FOR	AGAGGCAGAGGCTGTGACGAC	15818623-15819021	64.4	61.9	399
	REV	TTCGTGCGACAAAAGCGGACG		70.7	57.1	
DCP2_P18	FOR	TGCAATCGTCCGCTTTTGTGCGCA	15818995-15819495	73.6	52.2	501
	REV	AGAGGAAGGCGAGTTTTGAGCAGT		65.9	50.0	
DCP2_P19	FOR	TGCTCACCGAACTTTTTCGCGATCT	15819379-15819751	70.7	48.0	373
	REV	GTGCAACGGAAGGGAATCTAACTGT G		67.8	50.0	
DCP2_P20	FOR	CACAGTTAGATTCCCTTCCGTTGCAC	15819726- 15820171	67.8	50.0	446
	REV	ACAAAGCACGTCCAGGGCCA		68.4	60.0	

**TABLE S7** Overlapping set of primers to amplify the genomic region in *DCP2* gene for the region covered by the DCP2\_P19 set of primers in the homozygous *l(3)tb* mutant.

PRIMER SYMBOL	PRIMER DETAILS						
	PRIMER (10 pmol/ $\mu$ L)	SEQUENCE (5'→3')	TEMPLAT E STRAND	LENGT H (in ntd.)	MOLECULAR POSITIONS (FlyBase, R5)	Tm ( $^{\circ}$ C)	'GC' (%)
DCP2_P19_1	FOR	TAAATTGCCTTTATTTACACGTTGC	PLUS (+)	25	15819403-15819518	60.6	32.0
	REV	ACTATTTCTATACGCGACGCTGAAG	MINUS(-)	25		62.1	44.0
DCP2_P19_2	FOR	ACTATTTAACGGGCTTTTCAACTG	PLUS (+)	24	15819452-15819569	60.0	37.5
	REV	CGGTATATTTTGGTATCTTAGTGAGC	MINUS(-)	26		58.7	38.5
DCP2_P19_3	FOR	CAGCGTCGCGTATAGAAATAGTATG	PLUS (+)	25	15819497-15819622	67.7	46.2
	REV	AGTACATTTATCACAGAGCCTCAACTG	MINUS(-)	25		58.8	40.0
DCP2_P19_4	FOR	GCTCACTAAGATAACCAAATATACC G	PLUS (+)	26	15819544-15819657	58.7	38.5
	REV	AAAATAAGCAAATAACGTAAGACAG G	MINUS(-)	26		58.5	30.8
DCP2_P19_5	FOR	AAGCCTGTCTTACGTTATTTGCTTA	PLUS (+)	25	15819629-15819764	59.8	36.0
	REV	CAACTACAAGTAAGTGCAACGGAAG	MINUS(-)	25		61.4	44.0



**TABLE S8** Overlapping set of primers to amplify the complete 5'UTR of genomic region in *DCP2* gene in the homozygous *l(3)tb* mutant. The table also documents the thermal cycler conditions of annealing temperature and extension time for each primer pair. Genomic region amplified by primer pair is also mentioned.

PRIMER SYMBOL	PRIMER DETAILS					
	PRIMER (10 pmol/ $\mu$ L)	SEQUENCE (5'→3')	MOLECULAR POSITIONS (FlyBase, R5)	T <sub>m</sub> (°C)	'GC' (%)	AMPLICON SIZE (in bp)
DCP2_5'UTR1	FOR	GTACTCTAGTTATTCCATCGGTTGC	15819051-15819563	59.5	44.0	513
	REV	ATTTTGGTATCTTAGTGAGCAGCAT		59.6	36.0	
DCP2_5'UTR2	FOR	TTTTGCTATTGTTCTCTCGATTTTC	15819085-15819652	60.1	32.0	568
	REV	AAGCAAATAACGTAAGACAGGCTTT		60.8	36.0	
DCP2_5'UTR3	FOR	AAGCCTGTCTTACGTTATTTGCTTA	15819629-15820187	59.8	36.0	459
	REV	TCTGTTCTCTACGGATACAAAGCAC		61.0	44.0	

**TABLE S9 Three promoters for *Drosophila* gene *DCP2* are shown to provide transcriptional regulation for six transcripts.**

<b>Locus</b>	<b>Promoter ID/</b>	<b>Strand</b>	<b>Length</b>	<b>Transcript/TSS</b>
<b>Decapping Protein 2, DCP2 (GeneID:39722) DmelCG6169 GXL_196353</b>	GXP_235577 15817463-15818063 1 relevant transcript	Minus	601 bp	GXT_1658903 (5 Exons) NM_206378 (DCP2-RC)*** TSS=501
	GXP_622284 15817204-15817804 2 relevant transcript	Minus	601 bp	GXT_22014755 (5 Exons) NM_001014585 (DCP2-RD) TSS=501  GXT_25225584 (6 Exons) FBtr0100528 (DCP2-RD) TSS=501
<b>NCBI Build 5.41 Chromosome 3L Contig NT_037436</b>	GXP_622285 15819404-15820020 3 relevant transcript	Minus	617 bp	GXT_22014753 (5 Exons) NM_140548 (DCP2-RA) TSS=502  GXT_22014754 (5 Exons) NM_168634 (DCP2-RB) TSS=517  GXT_25225583 (5 Exons) FBtr0304975 (DCP2-RE) TSS=501

\*\*\* The NM\_206378 transcript has been removed from the database. ([www.genomatix.de](http://www.genomatix.de))